

BIBLIOGRAPHY

- Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010; 51: 1961–71.
- Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for Nonalcoholic Fatty Liver Disease: Results of a Randomized Placebo- Controlled Trial. *Hepatology* 2009; ;50(6):1818-26.
- Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol* 2009; 51: 918-924.
- Abiramasundari G, Sumalatha KR, Sreepriya M. Effects of *Tinospora cordifolia* on the proliferation, osteogenic differentiation and mineralization of osteoblast model systems in vitro. *J Ethnopharmacol* 2012;141(1):474-80.
- Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of non-alcoholic fatty liver disease. *Hepatology* 2004;40(2):475–83.
- AbuMweis SS, S Jew S, Ames NP. Beta-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. *European Journal of Clinical Nutrition* 2010; 64: 1472–1480.
- Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia* 2006;49(4):755-65.
- American Diabetes Association. Standards of medical care in diabetes–2013. *Diabetes Care* 2013;36:S11–66.
- American Diabetes Association, Standards of Medical Care in Diabetes 2014. *Diabetes Care* 2014; 37: S14-S80.
- American Diabetes Association. Management of dyslipidemia in adults with diabetes (Position Statement). *Diabetes Care* 2003; 26: S83–S86.
- Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol* 2005; 42: 132-8.
- Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005;129:113-121.
- Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. *CMAJ*. 2005;172:899–905.
- Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. *Diabet Med* 2005; 22(9): 1129-33.
- Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. *American Journal of Gastroenterology* 2010; 105 (7): 1567–1573.
- Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr Opin Lipidol* 2006; 17: 238-246.
- Adler M, Schaffber F. Fatty liver hepatitis and cirrhosis in obese patients. *Am J Med* 1979; 67: 811-16.
- Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, Marchesini G, Younossi ZM. Predictors of health-related quality of life in patients with chronic liver disease. *Ailment Pharmacol Ther* 2009; 30: 469-476.
- Agarwal O.P. Prevention of atheromatous heart disease. *Angiology*. 1985;36:485–92.
- Agius L. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. *Biochem Pharmacol*. 2013;85(3):306–12.
- Agrawal R, Mishra S, Dixit VK, Rai S. Non-Alcoholic Fatty Liver Disease And Metabolic Syndrome. *Indian J. Prev. Soc. Med*. 2011; 42 (3): 263-266.

- Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of *Momordica charantia* (karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. *Bangladesh Med Res Counc Bull.* 1999;25:11–3.
- Ahmed M. Non-alcoholic fatty liver disease in 2015. *World J Hepatol* 2015; 7(11): 1450–1459.
- Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. *The Year in Lipid Disorders*, 2007 C. J. Packard, Ed. 3–26, Clinical Publishing, Oxford, UK.
- Ahmed MH, Byrne CD. Non alcoholic steatohepatitis and metabolic syndrome, in *Metabolic Syndrome*, C. Byrne and S. Wild, Eds. 279–305, John Wiley & Sons, Chichester, UK, 2005.
- Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? *Drug Discov Today* 2010; 15: 590–595.
- Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? *Journal of Obesity*; 2012. 1-9.
- Aiyer KN, Kolammal M. *Pharmacognosy of Ayurvedic Drugs*, Series 1. 1st ed. Trivendram: The central Research institute; 1963.
- Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (*Embllica officinalis* Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. *Int J Food Sci Nutr* 2011;62:609–16.
- Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. *Int J Endocrinol* 2010; 35:1385.
- Alavian SM. Diabetes mellitus and fatty liver disease: which comes first? *Int J Endocrinol Metab.* 2010;8(3):130–1.
- Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. *Annals of Hepatology* 2009; 8(1): Supplement:S18–S24.
- Alwan A, Armstrong T, Cowan M, Riley L. Monitoring and surveillance of chronic noncommunicable diseases: progress and capacity in high-burden countries. *The Lancet*, 2010;376:1861–1868.
- Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. *Ann Hepatol* 2007; 6: 161–163.
- Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. *Trop Gastroenterol* 2004; 25: 130–4.
- Andrade AM, Greene GW, Melanson KJ. Eating slowly led to decreases in energy intake within meals in healthy women. *J Am Diet Assoc* 2008; 108: 1186–1191.
- Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol* 1991; 12: 224–229.
- Anderson R.A. Chromium and polyphenols from cinnamon improve insulin sensitivity. *Proc Nutr Soc* 2008;67:48–53.
- Anderson RA, Broadhurst CL, Polansky MM, editors. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *J Agric Food Chem* 2004;52:65–70.
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. *Hepatology* 1999;30:1356–62.
- Angulo P. Obesity and nonalcoholic fatty liver disease. *Nutrition Reviews* 2007;65:S57–63.
- Angulo P. NAFLD, obesity, and bariatric surgery. *Gastroenterology*. 2006;130:1848–1852.
- Angulo P. Medical progress: Nonalcoholic fatty liver disease. *N Engl J Med* 2002; 346:1221–31.
- Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Thorneau TM, Day CP. The NAFLD Fibrosis Score: a non invasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007; 45: 846–54.
- Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. *Clin. Sci. (Lond.)* 2004, 106, 635–643.

- Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factor of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010;51: 1972-1978.
- Asia Working Party on NAFLD: Executive Summary Guidelines for the assessment and management of Non-Alcoholic Fatty Liver Disease in the Asia-Pacific Region. *J Gastroenterol Hepatol.* 2007;22:775-7.
- Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. *World J Gastroenterol* 2009;15:1809–1815.
- Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. *Curr Med Res Opin* 2006; 22: 873-883.
- Attar BM, Van Thiel DH. Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease. *The ScientificWorld Journal* 2013, Article ID 481893, 10 pages.
- Augusti KT. Hypocholesterolemic effect of garlic (*Allium sativum* Lin). *Indian J Exp Biol.*1997; 15: 489.
- Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, Zanolin E, Schena F, Bonora E, Moghetti P. Both Resistance Training and Aerobic Training Reduce Hepatic Fat Content in Type 2 Diabetic Subjects With Nonalcoholic Fatty Liver Disease (the RAED2 Randomized Trial). *HEPATOLOGY* 2013;00:000-000. Pg1-9.
- Bairy KL, Rao Y, Kumar KL. Efficacy of *Tinospora cordifolia* on learning and memory in healthy volunteers: A double-blind, randomized, placebo controlled study. *Indian Journal of Pharmacology and Therapeutics.* 2004; 3: 57-60.
- Bajaj S, Nigam P, Luthra A, Pandey, RM, Kondal, D, Bhatt SP, Wasir, JS, Misra A. A case-control study on insulin resistance, metabolic co-variables & prediction score in non-alcoholic fatty liver disease. *Indian J Med Res.* 2009; 129(3):285-292.
- Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. *J Clin Endocrinol Metab.* 2004;89(1):200-206.
- Balfour L, Cooper C, Tasca GA, Kane M, Kowal J, Garber G. Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. *Can J Public Health* 2004;95:272–7.
- Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. *J Hepatol.* 2007;47:565–570.
- Banerjee S, Ghosh US, Dutta S. Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. *JAPI* 2008;56:593–9.
- Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. *Diabetes Care* 2008; 31: S61–S78.
- Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev* 2003;8:20–7.
- Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram E.R. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol.* 1990;30:295–300.
- Baumeister SE, Volzke H, Marschall P, John U, Schmidt CO, Flessa S, Alte D. Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. *Gastroenterology* 2008;134:85–94.
- Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; 42: 44-52.
- Behall KM, Scholfield DJ, Hallfrisch JG. Barley beta-glucan reduces plasma glucose and insulin responses compared with resistant starch in men. *Nutr Res* 2006; 26: 644–650.
- Behall KM, Scholfield DJ, Hallfrisch J. Lipids significantly reduced by diets containing barley in moderately hypercholesterolemic men. *J Am Coll Nutr* 2004; 23: 55–62.

- Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, DeFronzo RA, Cusi K. Dose-response effect of elevated plasma free fatty acid on insulin signaling. *Diabetes* 2005; 54: 1640–1648.
- Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; 355:2297–2307.
- Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). *Ann Hepatol* 2009;8(suppl 1):S4-S8.
- Bellentani S, Saccoccio G, Masutti F. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Am Intern Med* 2000; 132: 112-17.
- Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig. Dis.* 2010, 28, 155–161.
- Bellentani S, Grave RD, Suppini A, Marchesini G, and the Fatty Liver Italian Network (FLIN). Behavior Therapy for Nonalcoholic Fatty Liver Disease: The Need for a Multidisciplinary Approach. *HEPATOLOGY* 2008;47: 746-754.
- Berry D, Wathen JK, Newell M. Bayesian model averaging in meta analysis: vitamin E supplementation and mortality. *Clin Trials* 2009;6: 28-41.
- Bever B, Zahnd G. Plants with oral hypoglycemic action. *Quart J Crude Drug Res* 1979; 17:139-196.
- Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwittaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011; 54: 1208–1216.
- Bhandari PR, Kamdod MA. *Embllica officinalis* (Amla): A review of potential therapeutic applications. *Int J Green Pharm* 2012;6:257-69.
- Bhardwaj S, Misra A, Misra R, Goel K, Bhatt SP, Rastogi K, Vikram N.K, Gulati S. High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India. *PLoS One* 2011, 6, e24362.
- Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. *World J Hepatol.* 2012; 27;4(7):209-17.
- Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *Eur Heart J* 2012; 33: 1190–1200.
- Bhatia LS, Curzen NP and Byrne CD. Nonalcoholic fatty liver disease and vascular risk. *Current Opinion in Cardiology* 2012; 27: 20–428.
- Bhatia L, Byrne CD. There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. *Evid Based Med* 2010;15:84–85.
- Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. *HepatoBiliary Surg Nutr* 2015;4(2):101-108.
- Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Vidya M. SREBP-2 1784 G/C genotype is associated with non-alcoholic fatty liver disease in north Indians. *Dis. Markers* 2011, 31, 371–377.
- Bhatt RP, Sabnis SD. Contribution of the ethnobotany of khedbrahma region of north Gujarat. *Journal of Economic and Taxonomic Botany.* 1987; 9: 139-44.
- Bialek SR, Redd JT, Lynch A, Vogt T, Lewis S, Wilson C, Bell BP. Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003. *J Clin Gastroenterol.* 2008;42:949-54.
- Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. *Aliment. Pharmacol. Ther.* 2012; 35: 76–82.
- Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlström H, Risérus U. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. *Am. J. Clin. Nutr.* 2012; 95: 1003–12.
- Bjorntorp P. ‘Portal’ adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. *Arteriosclerosis* 1990;10:493–496.

- Bloomgarden ZT. Nonalcoholic fatty liver disease and Insulin Resistance in Youth. *Diabetes Care* 2007;30:1663-9.
- Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). *Diabetes Care*, 2008, 31:1132–1137.
- Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan V. Hba1c: predictor of dyslipidemia and atherogenicity in diabetes mellitus. *International Journal of Basic Medical Science* 2011; 2 (5): 278-282.
- Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. *Eur Radiol.* 2011;21(1):87-97.
- Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. *Diabetes Care* 2012; 35 (2): 389–395.
- Bonnefont-Rousselot D, Ratzliff V, Giral P, Charlotte F, Beucler I, Poynard T. Blood oxidative stress markers are unreliable markers of hepatic steatosis. *Alimentary Pharmacology and Therapeutics* 2006; 23 (1): 91–98.
- Bortolotti M, Kreis R, Debarb C, Cariou B, Faeh D, Chetiveaux M, Ith M, Vermathen P, Stefanoni N, Lê KA, Schneiter P, Krempf M, Vidal H, Boesch C, Tappy L. High protein intake reduces intrahepatocellular lipid deposition in humans. *Am. J. Clin. Nutr.* 2009; 90: 1002–10.
- Bortolotti M, Maiolo E, Corazza M, Van Dijke E, Schneiter P, Boss A, Carrel G, Giusti V, Lê KA, Quo Chong DG, Buehler T, Kreis R, Boesch C, Tappy L. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. *Clin. Nutr.* 2011; 30: 494–8.
- Bosworth T. Targeting the Trigger of Metabolic Syndrome, in *Gastroenterology & Endoscopy News*. Mc Mahon Publishing: New York. 2007.
- Bott U, Jörgens V, Grüsser M, Bender R, Mühlhauser I., Berger M. Predictors of glycaemic control in type I diabetic patients after participation in an intensified treatment and teaching programme. *Diabet Med.* 1994;11:362–371.
- Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA* 2001;286:1218-1227.
- Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arterioscler Thromb Vasc Biol* 2005;25(5):1045-50.
- Broca C, Manteghetti M, Gross R, Baissac Y, Jacob M, Petit P, Sauvaire Y, Ribes G. 4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion. *Eur J Pharmacol.* 2000; 390(3):339-45.
- Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology.* 2004;40:1387-95.
- Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. *Hepatology* 2006;44:466-71.
- Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 2004; 114: 147-152
- Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; 42 (5): 1208–1236.
- Budrat P, Shotipruk A. Extraction of phenolic compounds from fruits of bitter melon (*Momordica charantia*) with subcritical water extraction and antioxidant activities of these extracts. *Chiang Mai J Sci* 2008; 35(1): 123-130.
- Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. *Hepatology* 2005;42(5):987–1000.
- Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. *Diabetologia* 2005; 48 (4): 634– 642.
- Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic

- steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology*. 2002;123:134-40.
- Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. *Curr Diab Rep* 2007; 7:175–180.
 - Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. *Hepatology* 2004;39(1):179–87.
 - Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. *Best Pract Res Clin Gastroenterol* 2004; 18: 1105-1116.
 - Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. *Curr Pharm Des* 2010; 16: 1941-1951.
 - Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. *Hepatology* 2006; 44: 1648-1655.
 - Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *Am J Gastroenterol* 2005; 100: 1082-1090.
 - Bunyaphrathasara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. *Phytomed*. 1996;3:245–54.
 - Byrne CD. Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Review Article. Dorothy Hodgkin Lecture 2012. *Diabet. Med* 2012; 29: 1098–1107.
 - Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. *Clin Sci (Lond)* 2009;116:539–564.
 - Caceaux E. The relationship between non-alcoholic fatty liver disease and the metabolic syndrome. *Proc. Rom. Acad. Series B* 2012; 2: 143 – 150.
 - Cai Y, Wang Q, Ling Z, Pipeleers D, McDermott P, Pende M, Heimberg H, Van de Castele M. Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR. *Biochem Pharmacol*. 2008;75(10):1981–93.
 - Cai D, Yuan M, D. Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK- β and NF- κ B. *Nature Medicine* 2005; 11 (2): 183–190.
 - Caldwell S, Lee V. Cryptogenic cirrhosis. *AASLD Postgraduate Course* 2008; 48–57.
 - Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents. *J Clin Gastroenterol* 2006; 40 Suppl 1: S61-S66.
 - Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. *J Hepatol* 2004; 40: 578–84.
 - Calder PC. The relationship between the fatty acid composition of immune cells and their function. *Prostaglandins Leukot Essent Fatty Acids* 2008; 79: 101–108.
 - Campbell-Tofte JIA, Winther PMK. Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. *Botanics: Targets and Therapy* 2012;2 7–19.
 - Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovisca R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting non-alcoholic steatohepatitis in morbidly obese patients. *Hepatology* 2008;47(6):1916–23.
 - Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. *Aliment Pharmacol Ther* 2006; 23: 1143-1151.
 - Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, Greco AV, Gasbarrini G, Grieco A. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). *Eur Rev Med Pharmacol Sci* 2005; 9: 265-268.
 - Carey PE, Gerrard J, Cline GW, Dalla Man C, English PT, Firbank MJ, Cobelli C, Taylor R. Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production. *Am J Physiol Endocrinol Metab* 2005; 289: E941-E947.
 - Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. *Curr. Opin. Clin. Nutr. Metab. Care* 2012; 15: 468–73.

- Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. *Hepatology* 1999; 30: 1529-1530.
- Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, Messineo A, Surace M, Alicante S, Cotichini R, Zuin M, Rosmini F, Mele A, Marcucci F. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. *The American Journal of Epidemiology* 2010; 171 (11): 1195–1202.
- Cefalu WT, Ribnicky DM. Modulation of insulin action by botanical therapeutics. *Obes Weight Manag.* 2009;5:277–81.
- Cefalu WT, Stephens JM, Ribnicky DM. *Herbal Medicine: Biomolecular and Clinical Aspects*. 2nd edition. Chapter 19. Diabetes and Herbal (Botanical) Medicine. Benzie IFF, Wachtel-Galor S, editors. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
- Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. *American Journal of Gastroenterology* 2004; 99 (8): 1497– 1502.
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *AASLD practice guideline. Hepatology* 2012;55:2005-23.
- Chalasani N. It remains unclear whether simple steatosis is truly benign. *AGA Perspectives* 2008; February/March 2008.
- Chandra A, Sabharwal R, Chander R, Mahdi F, Mahdi AA. Effect of Some Indian Herbs on Dyslipidemia in Streptozotocin Induced Diabetic Rats, *Intern J Med Dental Sci* 2013; 2: 33.
- Chandrasekaran CV, Mathuram LN, Daivasigamani P, Bhatnagar U. T. cordifolia, a safety evaluation. *Toxicol in vitro.* 2009; 23: 1220-6.
- Chatrath H, Vuppalandhi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. *Semin Liver Dis* 2012; 32: 22-29.
- Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. *Cochrane Database Syst Rev* 2010;1:CD007340.
- Chen J, Mathew M, Finch J, Cusi K. The prevalence of NAFLD in T2DM is highest among Hispanics and is closely related to hepatic and adipose tissue insulin resistance [abstract]. *Diabetes* 2009; 58 (Suppl 1).
- Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. *Curr Opin Gastroenterol* 2009; 25: 230-237.
- Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. *Hepatology* 2002; 35: 373–379.
- Chitturi S, Farrell G, George J. Non alcoholic steatohepatitis in the Asia-Pacific region: Future Shock? *J Gastro Enterol Hepatol* 2004; 19: 368-74.
- Chopra RN, Chopra IL, Handa KL, Kapur LD (1958) *Indigenous Drugs of India*. (2nd edn), Calcutta: UNDhar and Sons Pvt. Ltd, pp. 314-316.
- Chougale AD, Ghadyale AD, Panaskar SN, Arvindekar AU. Alpha glucosidase inhibition by stem extract of *Tinospora cordifolia*. *J Enzyme Inhib Med Chem.* 2009; 24: 998-01.
- Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. *J. Clin. Gastroenterol.* 2006; 40: S39–S43.
- Clark SJ, Shojaee-Moradie F, Croos P, Seed PT, Umpleby AM, Wendon JA, Miell J. Temporal changes in insulin sensitivity following the development of acute liver failure secondary to acetaminophen. *Hepatology.* 2001;34(1):109–15.
- Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. *J Nutr* 2001; 131: 1129–1132.
- Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. *Am J Physiol Gastrointest Liver Physiol* 2001; 281: G865–G869.
- Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. *Curr Opin Lipidol* 2004; 15: 13–18.

- Clouston A, Powell E. Nonalcoholic fatty liver disease: Is all the fat bad? *Intern Med J.* 2004; 34: 187–191.
- Cobo Martin M, Fernandez Gil P, Crespo J. Treatment of fatty liver disease. *Gastroenterol Hepatol* 2008;31:229-38.
- Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. *Science* 2011; 322: 1519-1523.
- Colak Y, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic Fatty Liver Disease: A Nutritional Approach. *Metabolic Syndrome And Related Disorders* 2012;10 (3): 161-166.
- Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. *Diabetologia.* 2009;52(4):723-732.
- Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. *Cleveland Clin J Med*, 2004;71: 657–64.
- Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Review. Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). *Nutrients* 2013; 5: 4093-4114.
- Cook GC. Absorption products of D(-) fructose in man. *Clin Sci* 1969; 37: 675-687.
- Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. *Curr. Opin. Gastroenterol.* 2012; 28: 159–65.
- Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. *Best Pract Res Clin Gastroenterol* 2004; 18: 1089-1104.
- Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in nonalcoholic steatohepatitis patients? *Clin Nutr* 2006;25:816–823.
- Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: A randomized, controlled trial. *J Am Board Fam Med.* 2009;22:507–12.
- Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors in nonalcoholic steatohepatitis patients. *Hepatology* 2001; 34: 1158-1163.
- Criagg GM, David JN. Natural product drug discovery in the next millennium. *J. Pharm. Biol.* 2001; 39: 8-17.
- Criqui MH, Golom BA. Epidemiologic aspects of lipid abnormalities. *Am J Med.* 1998;105(Suppl 1A):48S–57S.
- Cusi K. Evolving concepts in lipotoxicity. *AASLD Postgraduate Course* 2008; 2008:72–84.
- Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. *Current Opinion in Endocrinology, Diabetes & Obesity* 2009; 16: 141-149.
- Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. *J Clin Endocrinol Metab* 2009; 94: 3842-3848.
- D’Albuquerque LA, Gonzalez AM, Wahle RC, de Oliveira Souza E, Mancero JM, de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. *Liver Transpl* 2008;14:881–5.
- da Luz PL, Favarato D, Faria-Neto Jr JR, Lemos P, Chagas ACP. High ratio of triglycerides to HDL-cholesterol ratio predicts extensive coronary disease. *Clinics.* 2008;63:427-32.
- Daly ME, Paisey R, Paisey R, Millward BA, Eccles C, Williams K, Hammersley S, MacLeod KM, Gale TJ. Short-term effects of severe dietary carbohydrate-restriction advice in type 2 diabetes—A randomized controlled trial. *Diabet. Med.* 2006; 23: 15–20.
- Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical followup in fatty liver patients. *Scand J Gastroenterol* 2009; 44: 1236– 1243.
- Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TIA, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut.* 2004;53:750–755.

- Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, Gerber L, Younossi ZM. Health-related quality of life in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2007;26:815-820.
- Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 2011;378(9785):31–40.
- Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* 2005, 111:1448–1454.
- Darukeshwara Joladarashi, Nandini D. Chilkunda, Paramahans Veerayya Salimath. Glucose uptake-stimulatory activity of *Tinospora cordifolia* stem extracts in Ehrlich ascites tumor cell model system. *J Food Sci Technol.* 2014; 51(1): 178–182.
- Das SK, Mukherjee S, Vasudevan DM. Non-alcoholic fatty liver disease: an underrecognized cause with emerging importance. *Current Science* 2006; 90 (5): 659-665.
- Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. *Eur J Clin Nutr* 2005; 59: 723-726.
- David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB, NASH CRN Research Group. Quality of Life in Adults with Nonalcoholic Fatty Liver Disease: Baseline Data from the Nonalcoholic Steatohepatitis Clinical Research Network. *Hepatology* 2009;49:1904-1912.
- Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? *Gastroenterol*, 1998;114:842–5.
- de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. *J Hepatol* 2008;48:Suppl 1:S104- S112.
- DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*, 2013; 227(2): 429–36.
- Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. *Nat Rev Cancer* 2005;5:930–42.
- Dencker H, Meeuwisse G, Norrby C, Olin T, Tranberg KG. Intestinal transport of carbohydrates as measured by portal catheterization in man. *Digestion* 1973; 9: 514-524.
- Devins GM, Mendelssohn DC, Barre PE, Taub K, Binik YM. Predialysis psychoeducational intervention extends survival in CKD: a 20-year follow-up. *Am J Kidney Dis* 2005;46:1088–98.
- Devprakash, Srinivasan KK, Subburaju T, Gurav S, Singh S. *Tinospora Cordifolia*: - A Review On Its Ethnobotany, Phytochemical & Pharmacological Profile. *Asian Journal of Biochemical and Pharmaceutical Research* 2011; 4 (1): 291-302.
- Devi VD, Urooj A. Nutrient profile and antioxidant components of *Costus speciosus* Sm. and *Costus igneus* Nak. *Indian J Nat Prod Resour.* 2010;1:116–8.
- Dey D, Mukherjee M, Basu D, Datta M, Roy SS, Bandyopadhyay A, Bhattacharya S. Inhibition of insulin receptor gene expression and insulin signaling by fatty acid: Interplay of PKC isoforms therein. *Cell. Physiol. Biochem.* 2005; 16: 217–28.
- Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. *Altern Med Rev.* 2002;7:45–58.
- de Wit NJW, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. *Journal of Hepatology* 2012 vol. 57 j 1370–1373.
- Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray C. Screening of Indian Plants for biological activity: Part I. *Indian J Exp Biol.* 1968;6:232–47.
- Dharel N, Fuchs M. Nonalcoholic Fatty Liver Disease – A Major Public Health Challenge for the 21st Century. *JSM Gastroenterol Hepatol* 2014; 2(2): 1018.
- Diehl AM. Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis. *Alcoholism* 2001; 25 (5): 8S–14S.
- Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. *Clinics in Liver Disease* 2004; 8 (3): 619–638.
- Dietrich M, Jacques PF, Pencina MJ, Lanier K, Keyes MJ, Kaur G, Wolf PA, D’Agostino RB, Vasan RS. Vitamin E supplement use and the incidence of cardiovascular disease and all-

- cause mortality in the Framingham Heart Study: Does the underlying health status play a role? *Atherosclerosis* 2009;205:549-553.
- Dikshit V, Damre AS, Kulkarni KR, Gokhale A, Saraf MN. Preliminary screening of imunocin for immunomodulatory activity. *Indian J Pharm Sci* 2000; 62: 257.
 - Dineshkumar B, Mitra A, Mahadevappa M. Antidiabetic and hypolipidemic effects of mahanimbine (carbazole alkaloid) from *Murraya koenigii* (Rutaceae) leaves[J]. *Int J Phytomed*, 2010; 2(1):22-30.
 - Dobiasova M. Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]:Theoretical and Practical Implications. Editorial. *Clinical Chemistry* 2004; 50 (7): 1113-115.
 - Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. *World J Gastroenterol* 2008; 14: 695–700.
 - Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* 2005; 115:1343–1351.
 - Dorman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2011;33:525–540.
 - Dorman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. *QJM* 2010; 103: 71-83.
 - Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. *N Engl J Med* 1970;282: 829–830.
 - Dugoua JJ, Seely D, Perri D, Cooley K, Forelli T, Mills E, Koren G. From type 2 diabetes to antioxidant activity: A systematic review of the safety and efficacy of common and cassia cinnamon bark. *Can J Physiol Pharmacol*. 2007;85:837–47.
 - Dugoni M, Miglioli L, Borelli L, Anderlini R, Bedogni G, Mariano M, Battistini MN, Bellentani S. Doppler perfusion index (DPI) and homa are highly predictive of fatty liver in patients with NAFLD. *Dig Liver Dis*. 2008;40 (5):A39.
 - Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of seed and soil. *Am J Gastroenterol* 2010; 105: 613-620.
 - Dunn S.M. Reactions to educational techniques: coping strategies for diabetes and learning. *Diabet Med*. 1986; 3: 419–429.
 - Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. *J Biol Chem*. 2005;280(33):29971–9.
 - Duseja A. Nonalcoholic fatty liver disease in India: A lot done, yet more required! *Indian J Gastroenterol* 2010;29:217-25.
 - Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK, Chawla YK. Nonalcoholic fatty liver disease in a developing country is responsible for significant liver disease. *Hepatology* 2010; 52: 2248-9.
 - Duseja A, Das A, Dhiman RK, Chawla YK, Das R, Bhadada S, Sialy R, Thumburu KK, Bhansali A, Kalra N. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. *World J Gastroenterol*. 2007;13:649–50.
 - Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. Clinicopathological profile of Indian patients with nonalcoholic fatty liver disease is different from that in the west. *Dig Dis Sci*. 2007;52:2368–74.
 - Duseja A, Bhansali A, Bhadaba S, Jain P, Dhiman RK, Chawla Y. Nonalcoholic fatty liver disease in subjects with recent onset type 2 diabetes mellitus. *J Gastroenterol Hepatol* 2004; 19 Suppl:A402.
 - Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. *Frontline Gastroenterology* 2014;0:1–10.
 - Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, Harrison SA. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. *Therap Adv Gastroenterol*. 2013; 6(4): 249–259.
 - Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: Human data. *Clin Liver Dis* 2007;11:75-104.

- Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; 44: 865-873.
- Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, Koteish AA, Clark JM, Guallar E, Hernaez R. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2013; 38: 246–254.
- Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. *Int J Hepatol* 2012; 925807: 1-6.
- Enjoji M, Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? *World J Gastroenterol* 2010; 16(7): 800-803.
- Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). *Eur J Med Res* 2011; 16: 76-78.
- Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Cochrane Database Syst Rev* 2013;12:CD008623.
- Evans J.L. Diet, botanical, and nutritional treatments for type 2 diabetes. 2003.
- Everhart JE, Bambha KM. Fatty liver: think globally. *Hepatology* 2010; 51: 1491-1493.
- Jian-Gao Fan, Hai-Xia Cao. Role of diet and nutritional management in non-alcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology* 2013; 28 (Suppl. 4): 81–87.
- Jian-Gao Fan, Yong-De Peng. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. *Hepatobiliary Pancreat Dis Int* 2007; 6 (6): 572-578.
- Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? *J Am Diet Assoc* 2007;107:92-99.
- Farooqi A, Vasundra M, Agarwal A. *Production Technology of Medicinal and Aromatic Crops*, 4th edition, Medicinal Plant Research and Development, Bangalore, 2001; 124-125.
- Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. *Gut Liver* 2012; 6: 149–171.
- Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? *J Gastroenterol Hepatol* 2003; 18: 124-138.
- Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, and McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. *Hepatology* 2009; 50 (4): 1072–1078.
- Felicia W, Lakshminarayan S, Hariprasad C. Effect Of Some Indian Vegetables On The Glucose And Insulin Response In Diabetic Subjects, *Int. J. Food. Sci. Nutr* 1993; 44(3):191-196.
- Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized *Momordica charantia* fruit extract. *BMC Complement Altern Med*. 2007;7:29.
- Fernández A, Colell A, Garcia-Ruiz C, Fernandez- Checa JC. Cholesterol and sphingolipids in alcohol-induced liver injury. *Journal of Gastroenterology and Hepatology* 2008; 23 (1) supplement 1, S9–S15.
- Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. *Dig Liver Dis* 2008; 40: 200-205.
- Ferolla SM, Ferrari TCA, Lima MLP, Reis OT, Tavares-Jr WC, Osvaldo Couto FM, Vidigal PVT, Maria Arlene Fausto, Couto VCA. Dietary patterns in Brazilian patients with non-alcoholic fatty liver disease: a cross-sectional study. *Clinics*. 2013;68(1):11-17.
- Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. *Aliment Pharmacol Ther* 2013; 37: 392-400.
- Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. *Obesity reviews* 2004; 5: 27-42.
- Finelli C, Tarantino G. Is visceral fat reduction necessary to favour metabolic changes in the liver? *J Gastrointest Liver Dis* 2012a;21:205-8.
- Finelli C, Tarantino G. Review article. Nonalcoholic Fatty Liver Disease, Diet And Gut Microbiota. *EXCLI Journal* 2014;13:461-490.

- Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? *World J Gastroenterol* 2014; 20(27): 9072-9089.
- Fischer GE, Bialek SP, Homan CE, Livingston SE, McMahon BJ. Chronic liver disease among Alaska-Native people, 2003–2004. *Am J Gastroenterol*. 2009;104:363-70.
- Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. *J Hepatol* 2010; 52: 112-116.
- Frohlich J, Dobiášová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. *Clin Chem* 2003; 49: (11) 1873-1880.
- Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). *Am J Cardiol*. 2007;100:64–68.
- Gaby AR. Adverse effects of dietary fructose. *Altern Med Rev* 2005; 10: 294-306.
- Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Eng J Med* 2003; 348: 383-93.
- Gagan VD, Pradhan P, Sipahimalan AT, Banerji A, Palmatosides C. F: Diterpene furan glucosides from *Tinospora cordifolia*-Structural elucidation by 2D-NMR spectroscopy. *Indian Journal of Chemistry-Organic Medicinal Chemistry*. 1996; 35: 630-4.
- Gagan VD, Pradhan P, Sipahimalani AT, Banerji A. Cordifoliosides A, B, C: Norditerpene furan glycosides from *Tinospora cordifolia*. *Phytochemistry*. 1994; 37: 781-6.
- Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients* 2013; 5: 1544–1560.
- Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Annals of Medicine* 2011;43(8):617-49.
- Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, DeFronzo RA. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. *Gastroenterology* 2007; 133:496–506.
- Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B, The RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. *Hepatology* 2009; 49: 1537–1544.
- Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. *Circulation* 1997; 96: 2520-5.
- Gentile C, Pagliassotti M. The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease. *Curr Opin Investig Drugs* 2008; 9:1084–1088.
- Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality – inconsistent results of different meta-analytic approaches. *Cell Mol Biol* 2009;55 Suppl: OL 1111-20.
- Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? *World J Gastroenterol* 2006; 21; 12(3): 345-353.
- Grogan A, Timmins F. Patients' perceptions of information and support received from the nurse specialist during HCV treatment. *J Clin Nurs* 2010;19:2869–78.
- Gupta AK, Gupta N, Sharma M. Indian Council of Medical Research. Quality standards of Indian medicinal plants. New Delhi: Indian Council of Medical Research 2003; 1:212.
- Ghamar-Chehreh ME, Khedmat H, Karbasi A, Amini M, Taheri S. Predictive factors for ultrasonographic grading of non-alcoholic fatty liver disease. *Hepat Mon* 2012; 12 (11): e6860: 1-4.
- Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J, Anand S. Knowing what's out there: awareness of non-alcoholic fatty liver disease. *Front. Med*. 2014; 1:4. doi: 10.3389/fmed.2014.00004
- Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. *Am. J. Gastroenterol*. 2007; 102: 399–408.

- Glasgow RE, Osteen VL. Evaluating diabetes education: are we measuring the most important outcomes? *Diabetes care*. 1992;15:1423-1432.
- Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol*. 2007; 18; 99(12A):4i-20i.
- Gohel MG, Chacko AN. Serum GGT activity and hsCRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control. *Journal of Diabetes & Metabolic Disorders* 2013; 12:56:1-8.
- Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. *Annu Rev Med* 1998; 49: 235-261.
- Gopalpura PB, Jayanthi C, Dubey S. Effect of *Trigonella foenum-graecum* seeds on the glycemic index of food: A clinical evaluation. *Int J Diab Dev Ctries*. 2009;27:41–5.
- Gorstein J, Sullivan KM, Parvanta I, Begin F. Indicators and methods for cross-sectional surveys of vitamin and mineral status of populations. *Micronutrient Initiative (Ottawa) and Centers for Disease Control and Prevention (Atlanta)*. 2007; 29.
- Grattagliano I, D'Ambrosio G, Palmieri VO, Moschetta A, Palasciano G, Portincasa P, "Steatostop Project" Group. Improving Nonalcoholic Fatty Liver Disease Management by General Practitioners: a Critical Evaluation and Impact of an Educational Training Program. *J Gastrointest Liver Dis*. 2008;17(4): 389-394.
- Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. *British Society of Gastroenterology. Gut* 1999; 45 Suppl 4: IV1-IV11.
- Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, Schwarz P; IMAGE Study Group. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. *BMCPublic Health*. 2011;11(1):119.
- Grover JK, Yadav SP. Pharmacological actions and potential uses of *Momordica charantia*: A review. *J Ethnopharmacol*. 2004;93:123–32.
- Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. *J Ethnopharmacol*. 2002;81:81–100.
- Grover P, Bansal G. *Tinospora Cordifolia* (Thunb): An Indispensable and Standardized Herb. *RRJAYUSHP* 2012; 1 (1): 1-13.
- Guerrero-Romero F, Rodríguez-Morán M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. *Archives of Medical Research*. 2003; 34 (5): 428-32.
- Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Nonalcoholic steatohepatitis in type 2 diabetes mellitus. *J Gastroenterol Hepatol* 2004; 19: 854-8.
- Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of β -cell death and dysfunction. *Trends Cell Biol* 2011; 21: 424-431.
- Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 2011; 60: 1278-1283.
- Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* 2005; 143: 722-728.
- Hamaguchi M, Kojima T, Takeda N. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. *World J Gastroenterol* 2007; 13: 1579-84.
- Han Y, Shi JP, Ma AL, Xu Y, Ding XD, Fan JG. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic Fatty liver disease patients with impaired fasting glucose. *Clin Drug Investig* 2014; 34: 1-7.
- Hanak V, Munoz J, Teaque J, Stanley A Jr, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. *Am J Cardiol*. 2004;94:219-22.
- Hannukainen JC, Nuutila P, Borra R, Kaprio J, Kujala UM, Janatuinen T, Heinonen OJ, Kapanen J, Viljanen T, Haaparanta M, Rönnemaa T, Parkkola R, Knuuti J, Kalliokoski

- KK. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. *J Physiol (Lond)* 2007;578:347-358.
- Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. *Hepatology* 2009;50:1403-11.
 - Harris EH. Elevated liver function tests in Type 2 Diabetes. *Clinical Diabetes* 2005;23:115-9.
 - Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut* 2008;57(10):1441-7.
 - Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. *J Gastroenterol*. 2009;44 Suppl 19:89-95.
 - Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulou A, Karagiannopoulou G, Tzioufa V, Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. *Indian J. Gastroenterol*. 2004; 23: 131-134.
 - Havel PJ. Dietary fructose: Implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. *Nutr Rev* 2005;63:133-157.
 - Hegde PK, Rao HA, Rao PN. A review on Insulin plant (*Costus igneus* Nak). *Pharmacogn Rev*. 2014; 8(15): 67-72.
 - Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. *Lipids in Health and Disease* 2012; 11(132):1-8.
 - Hermans MP, Ahn SA, Rousseau MF. Log(TG)/HDL-C is related to both residual cardiometabolic risk and β -cell function loss in type 2 diabetes males. *Cardiovasc Diabetol* 2010, 9:88.
 - Hermans MP, Ahn SA, Rousseau MF. The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA₁ ratio in diabetics: Comparison with reference lipid markers. Michel P. Hermans *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2007; 1 (1): 23-28.
 - Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011; 54: 1082-90.
 - Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. *Gut*. 2004;53:413-419.
 - Hinata M, Ono M, Midorikawa S, Nakanishi K. Metabolic improvement of male prisoners with type 2 diabetes in Fukushima Prison, Japan. *Diabet Res Clin Pract* 2007; 77: 327-332.
 - Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. *J Lipid Res* 2011; 52: 593-617.
 - Hosseini-panah F, Rambod M, Sadeghi L. Predictors of Non-Alcoholic Fatty Liver Disease in type 2 Diabetes. *Int J Endocrinol Metab* 2007; 2: 61-69.
 - Hsiao PJ, Kuo KK, Shin SJ. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. *J Gastroenterol Hepatol* 2007; 22: 2118-23.
 - Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. *Obes. Surg.* 2007; 17: 1457-1463.
 - Huang MA, Greenon JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: A pilot study. *Am J Gastroenterol* 2005;100:1072-1080.
 - Hui JM, Farrell GC, Kench JG, and George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. *Hepatology* 2004; 39 (5): 1458-1459.
 - Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. *Hepatology*. 2003;38:420-7.

- Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. *J Nutr Biochem* 2011; 22: 699-711.
- Ibrahim SH, Gores GJ. Who pulls the trigger: JNK activation in liver lipotoxicity? *J Hepatol* 2012; 56: 17-19.
- International Diabetes Federation, 2013. IDF diabetes atlas, 6th edition.
- Worldwide definition of metabolic syndrome. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation (IDF), 2006; 366:1059-62.
- International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot International Working Group on the Diabetic Foot; 1999.
- Guidelines for data processing and analysis of the international physical activity questionnaire (IPAQ)- short and long forms. November, 2005.
- Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006; 113: 195-202.
- Iyer U, Desai PA, Venugopal S. Impact of panchratna juice in the management of diabetes mellitus: Fresh vs. processed product. *International Journal of Green Pharmacy* 2010; 122-128.
- Iyer UM, Mani UV. Studies on the effect of curry leaves supplementation (*Murraya koenigii*) on lipid profile, glycated proteins and amino acids in non-insulin-dependent diabetic patients. *Plant Foods Hum Nutr*. 1990; 40(4): 275-282.
- Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE. Hepatic CTP: phosphocholine cytidyltransferase- α is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. *J Biol Chem* 2008; 283: 2147-2155.
- Jain V, Momin M, Laddha K. *Murraya Koenigii*: An Updated Review. *International journal of ayurvedic & herbal medicine*. 2012; 2 (4):607-627.
- James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. *Journal of Hepatology* 1998; 29 (3): 495–501.
- Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. *Obesity Surgery* 2005; 15 (4): 497–501.
- Jarvill-Taylor KJ, Anderson RA, Graves DJ. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. *J Am Coll Nutr*. 2001;20:327–36.
- Jayarama N, Sudha R. A Study of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus in a Tertiary Care Centre, Southern India. *Journal of Clinical and Diagnostic Research* 2012; 6(2): 243-245.
- The Eight Report Of The Joint National Commiittee On Prevention, Detection, Evaluation And Treatment Of High Blood Pressure (JNC 8), 2013.
- Jee V, Dar GH, Bhat GM. Taxoethnobotanical studies of the rural areas in district Rajouri (Jammu). *Journal of Economic and Taxonomic Botany*. 1984; 5: 831-4.
- Jennings AR. Assessing educational needs of potential hepatitis C patients at a Veterans Affairs medical center. *Educ Health (Abingdon)* 2011;24:532.
- Ji-Young Cho, Tae-Heum Chung, Kyoung-Mo Lim, Hee-Jin Park, Jung-Mi Jang. The Impact of Weight Changes on Nonalcoholic Fatty Liver Disease in Adult Men with Normal Weight. *Korean J Fam Med*. 2014;35:243-250.
- Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology* 2009;50:1105–1112.
- Jose B, Reddy LJ. Analysis of the essential oils of the stems, leaves and rhizomes of the medicinal plant *Costus pictus* from southern India. *Int J Pharmacy Pharm Sci*. 2010;2(Suppl 2):100–1.
- Joseph B, Jini D. Insight into the hypoglycaemic effect of traditional Indian herbs used in the treatment of diabetes. *Res. J. Med. Plant* 2011; 5: 352-376.
- Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. *Stroke* 2000; 31: 1851–1855.
- Juurinen L, Kotronen A, Graner M, Yki-Jarvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. *J Clin Endocrinol Metab* 2008;93:118–24.

- Juurinen L, Tiikkainen M, Hakkinen AM, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007;292:E829–35.
- Kadama Y, Ng CS, Wu TT. Comparison of CT methods for determining the fat content of the liver. *Am J Roentgenol* 2007;188: 1307-1312.
- Kakkos SK, Yarmenitis SD, Tsamandas AC, Gogos CA, Kalfarentzos F. Fatty liver in obesity: relation to Doppler perfusion index measurement of the liver. *Scand J Gastroenterol* 2000; 35:976–980.
- Kalikar M, Thawani V, Varadpande U, Sontakke S, Singh R, Khiyani R. Immunomodulatory effect of *Tinospora cordifolia* extract in human immune-deficiency virus positive patients. *Indian Journal of Pharmacology*. 2008; 40: 107-10.
- Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. *Dig Dis Sci*. 2008;53: 1358-63.
- Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, Das B, Sahay R, Modi KD. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). *J Assoc Physicians India*. 2013; 61(7):448-53.
- Kamble SM, Kamalakar PL, Vaidya S, Bambole VD. Influence of *Coccinia indica* on certain enzymes in glycolytic and lipolytic pathway in human diabetes. *Indian J. Med. Sci* 1998; 52: 143–146.
- Kang H, Greenston JK, Omo JT, Chao C, Peterman D, Anderson L, Foess-Wood L, Sherbondy MA, Conjeevaram HS. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. *Am. J. Gastroenterol*. 2006; 101: 2247–2253.
- Kani AH, Alavian SM, Haghighatdoost F, Azadbakht L. Diet Macronutrients Composition in Nonalcoholic Fatty Liver Disease: A Review on the Related Documents. *Hepat Mon*. 2014; 14(2): e10939. 1-9.
- Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Königsrainer A, Königsrainer I, Kröber S, Niess A, Fritsche A, Häring HU, Stefan N. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. *Gut* 2009; 58: 1281-1288.
- Karkal YR, Bairy LK. Safety of aqueous extract of *Tinospora cordifolia* in healthy volunteers: A double blind randomized placebo controlled study. *Iranian Journal of Pharmacology and Therapeutics*. 2007; 6: 59-61.
- Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. *Int J Clin Pract* 2010;64:968-83.
- Kassaian N, Azadbakht L, Forghani B, Amini A. Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients. *Int J Vitam Nutr Res*. 2009;79:34–9.
- Katan MB. Weight-loss diets for the prevention and treatment of obesity. *N Engl J Med* 2009; 360: 923-925.
- Katcher HI, Legro RS, Kunselman AR, Gillies PJ, Demers LM, Bagshaw DM, Kris-Etherton PM. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. *Am J Clin Nutr* 2008; 87: 79-90.
- Kavishankar GB, Lakshmidhevi N, Murthy SM, Prakas HS, Niranjana SR. Diabetes and medicinal plants-A review. *Int J Pharm Biomed Sci* 2011; 2(3): 65-80.
- Kawai H, Nomoto M, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Yano M, Takamura M, Igarashi M, Wakai T, Yamagiwa S, Matsuda Y, Ohkoshi S, Kurosaki I, Shirai Y, Okada M, Aoyagi Y. Multicentric occurrence of hepatocellular carcinoma with non-alcoholic steatohepatitis. *World J Hepatol* 2011; 3: 15–23.
- Keenan JM, Goulson M, Shamliyan T, Knutson N, Kolberg L, Curry L. The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. *Br J Nutr* 2007; 97: 1162–1168.
- Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. *Hepat Mon* 2013;13:e7233.
- Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. *Diabetes* 2000; 49: 677-683.
- Khan A, Safdar M, Ali Khan MM, Khatkhat KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diab Care*. 2003;26:3215–8.

- Khan A, Bryden NA, Polansky MM, and Anderson RA. Insulin potentiating factor and chromium content of selected foods and spices. *Bio. Trace. Element Res.* 1990; 24: 183-188.
- Khare CP. *Indian Medicinal Plants - An Illustrated Dictionary*. 1st Ed. Springer Science and Business Media LLC; 2007.
- Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. *BioMed Research International* Volume 2014, Article ID 106247, 6 pages.
- Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR. Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology* 2012; 56 (2): 605–613.
- Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. *Atherosclerosis* 2009; 204 (2): 521–525.
- Kim CH, Younossi Z. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. *Cleveland Clinic Journal Of Medicine* 2008; 75 (10): 721-728.
- Kirpich IA, McClain CJ. Probiotics in the treatment of the liver diseases. *J Am Coll Nutr* 2012; 31: 14-23.
- Kirtikar KR, Basu BD. *Indian Medicinal Plants*. International Book Distributors, Dehradun, India, 1987;1: 77-80.
- Kizer E, Whitehead A, Indest D, Hauser P. Efficacy of group education in veterans with hepatitis C. *Fed Pract* 2006;23:50–7.
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. *Hepatology* 2005; 41 (6): 1313–1321.
- Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. *Ther. Adv. Gastroenterol.* 2012; 5: 199–207.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New Engl J Med.* 2002;346:393–403.
- Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. *J Hepatol.* 2012; 57: 1305-1311.
- Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. *Mol Cell Endocrinol* 2013; 379: 35-42.
- Konda VGR, Madhavi E, Ruckmani A, Venkataramana Y. A review on medicinal plants with potential hypolipidemic activity. *Int J Pharm Bio Sci.* 2013; 4:729-40.
- Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. *J Clin Endocrinol Metab*, 2007;92:3490–97.
- Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, Yki-Järvinen H. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. *Diabetes Care* 2008; 31(1): 165-9.
- Kotronen A, Yki-Jarvinen H. Fatty liver. A novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008; 28: 27– 38.
- Kotronen A, Seppälä-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, Yki-Järvinen H. Liver fat and lipid oxidation in humans. *Liver International* 2009; 29 (9): 1439–1446.
- Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. *Gastroenterology* 2010;138:817-819.
- Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, and Nelson JE for the NASH Clinical Research Network. Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease. *Hepatology* 2012; 55(1): 77–85.
- Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E; RISC Investigators. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. *Hepatology* 2012; 55 (5): 1406–1415.
- Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. *Metabolism* 1993; 42: 548-551.

- Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 2008; 47 (4):1158–1165.
- Krass I, Dhippayom T. Pharmaceutical care – impact on quality of life in patients with type 2 diabetes: a review. *Clinical Audit*. 2013;5 17–32.
- Kratzer W, Fritz V, Mason RA, Haenle MM, Kaechele V. Factors Affecting Liver Size A Sonographic Survey of 2080 Subjects. *J Ultrasound Med* 2003; 22:1155–1161.
- Krishna KL, Bhatt J, Patel J. Guduchi (*Tinospora cordifolia*): Biological and medicinal properties, a review. *Internet J Altern. Med* 2009;6(2).
- Krishnan A, Venkataraman J. Prevalence of nonalcoholic fatty liver disease and its biochemical predictors in patients with type-2 diabetic mellitus. *E&C Hepatology*, 2011; 7(3-4): 7-10.
- Kumar V. Antidyslipidemic and Antioxidant Activities of *Tinospora cordifolia* Stem Extract in Alloxan Induced Diabetic Rats. *Indian Journal of Clinical Biochemistry*. 2015; DOI 10.1007/s12291-015-0485-1.
- Kumar A, Kumar M, Dandapat S, Sinha MP. Antioxidant Activity And Pharmacological Screening Of *Tinospora Cordifolia* (Thunb.) The Bioscan 2013; 8(2): 689-693.
- Kundnani KM, Mahajan VR, Jolly CI. A new hypoglycaemic agent from *Tinospora cordifolia*: Miers. *Indian Drugs*. 1985;23:119–20.
- Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology* 2003;38:413-419.
- Kumar S, Verma NS, Pande D, Srivastava PS. In vitro regeneration and screening of berberine in *Tinospora cordifolia*. *J Med Arom Plant Sci* 2000; 22:61.
- Kurpad AV, Raj R. The Effect Of Ivy Gourd (*Coccinia Cordifolia*) Extract On Diabetic Patients. *Bulletin of Nutrition Foundation Of India (NFI)*. 2002; 1:1-5.
- Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. *J Biol Chem*. 1995; 270:15285–15293.
- LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Penaranda MM, Ramos JFR, Sarin S, Stimac D, Thomson ABR, Umar M, Krabshuis J and LeMair A. World Gastroenterology Organisation Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *J Clin Gastroenterol*. 2014; 48 (6): 467-473.
- Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007;370:1129–36.
- Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. *Ther Adv Gastroenterol* 2010; 3(2): 121-137.
- Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. *J Gastroenterol Hepatol* 2010; 25: 672-90.
- Lather A, Gupta V, Bansal P, Sahu M, Sachdeva K, Ghaiye P. An Ayurvedic polyherbal formulation Kaishore Guggulu: a review. *Int J Pharm Biol*. 2011; 2(1): 497-503.
- Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KE, Knuuti J, Parkkola R, Nuutila P. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. *Am J Physiol Endocrinol Metab* 2006;291: E282-E290.
- Lawson LD, Bauer R. Garlic: A review of its medicinal effects and indicated active compounds. *American Chemical Society* 1998; 176–209.
- Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Epidemiol* 2013; 178: 38-45.
- Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM. Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010; 33: 2156–2163.
- Leach MJ. *Gymnema sylvestre* for diabetes mellitus: A systematic review. *J Altern Complement Med*. 2007;13:977–83.

- Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. *Curr Osteoporos Rep* 2010;8:178–84.
- Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutrition management. *Curr Opin Clin Nutr Metab Care* 2008; 11: 766-73.
- Ledikwe JH, Ello-Martin JA, Rolls BJ. Portion sizes and the obesity epidemic. *J Nutr* 2005; 135: 905-909.
- Leen E, Goldberg JA, Angerson WJ, McArdle CS. Potential role of Doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. *Lancet*. 2000; 355:34–37.
- Leidy HJ, Mattes RD, Campbell WW. Effects of acute and chronic protein intake on metabolism, appetite, and ghrelin during weight loss. *Obesity (Silver Spring)*. 2007;15(5):1215–25.
- Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, Boesch C, Ravussin E, Tappy L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. *Am J Clin Nutr* 2006; 84: 1374-1379.
- Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. *Liver Int*. 2009;29:113-9.
- Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. *Liver Int* 2011; 31: 700-706.
- Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Anti-diabetic and hypoglycemic effects of *Momordica charantia* (bitter melon): A mini review. *Br J Nutr*. 2009;102:1703–8.
- Leung CM, Lai LS, Wong WH, Chan KH, Luk YW, Lai JY, Yeung YW, Hui WM. Non-alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong. *J Gastroenterol Hepatol*. 2009; 24(11):1786-90.
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. *Annals of Internal Medicine* 2009; 150 (9): 604-12.
- Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. *Digestive Diseases and Sciences* 2010; 55 (3): 560–578.
- Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: A scientific statement from the american heart association nutrition committee. *Circulation* 2006, 114, 82–96.
- Linn T, Geyer R, Prassek S, Laube H. Effect of dietary protein intake on insulin secretion and glucose metabolism in insulindependent diabetes mellitus. *J Clin Endocrinol Metab* 1996;81:3938–3943.
- Linn T, Santosa B, Grönemeyer D, Aygen S, Scholz N, Busch M, Bretzel RG. Effect of long-term dietary protein intake on glucose metabolism in humans. *Diabetologia* 2000;43:1257–1265.
- Lippman SM, Klein EA, Goodman PJ, Claudio J, Winkquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2009;301:39–51.
- Liu S, Willett WC, Stampfer MJ, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JAE. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. *Am J Clin Nutr* 2000; 71:1455–1461.
- Li Z, Clark J, Diehl AM. The liver in obesity and type 2 diabetes mellitus. *Clin Liver Dis*, 2002;6:867–77.
- Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearyl-CoA desaturase. *J Biol Chem* 2009; 284: 5637-5644.
- Lincoff A, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. *JAMA* 2007;298:1180-1188.

- Lindor KD, Kowdley KV, Luketic VA, Harrison ME, Mc- Cashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology* 2009; 50: 808-814.
- Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology* 2004; 39: 770-778.
- Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. *J Diabetes Complications* 2007;21:137-42.
- Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database Syst. Rev.* 2007, CD004996, doi:10.1002/14651858.CD004996.pub3.
- Listenberger LL, Han X, Lewis SE, Cases S, Farese RV, Ory DS, Schaffer JE. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. *Proc Natl Acad Sci USA* 2003; 100:3077-3082.
- Loguercio C, Girolamo VD, Sio ID, Tuicillo C, Ascione A, Bald F. Nonalcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. *J Hepatol* 2001;35:568-74.
- Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, Bernard BD, Tiribelli C, Palma LD. Proton mr spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. *J Magn Reson Imaging* 1995;5:281-5.
- Longuet C, Sinclair EM, Maida A, Baggio LL, Maziarz M, Charron MJ, Drucker DJ. The glucagon receptor is required for the adaptive metabolic response to fasting. *Cell Metab.* 2008;8(5):359-71.
- Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol.* 2013;10(11):686-90.
- Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 2012;56:943-51.
- Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. *Science* 2005; 307: 384-387.
- Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. *International Journal of Endocrinology.* Volume 2013 (2013), Article ID 124958, 7 pages.
- Ludwig J, Viaggiano TR, McGill DB, Oh BJ. Non-alcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55: 434-8.
- Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with non-alcoholic steatohepatitis. *Hepatology* 2007; 46: 424-429.
- Luyckx FH, Desai C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *Int J Obes Relat Metab Disord* 1998;22:222-6.
- Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. *J Hepatol* 2006; 45: 600-606.
- Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T, Baldeiras I, Camilo ME, Cortez-Pinto H. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. *Scand J Gastroenterol* 2008;43:95-102.
- Madan K, Batra Y, Panda SK, Dattagupta S, Hazari S, Jha JK, Acharya SK. Role of polymerase chain reaction and liver biopsy in the evaluation of subjects with asymptomatic transaminitis. Implications in diagnostic research. *J Gastroenterol. Hepatol* 2004; 20: 1291-9.
- Madigan C, Ryan M, Owens D, Collins P, Tomkin GH. Dietary unsaturated fatty acids in type 2 diabetes: higher levels of postprandial lipoprotein on a linoleic acid-rich sunflower oil diet compared with an oleic acid-rich olive oil diet. *Diabetes Care.* 2000;23(10):1472-7.
- Maersk M, Belza A, Stødkilde-Jørgensen H, Ringgaard S, Chabanova E, Thomsen H, Pedersen SB, Astrup A, Richelsen B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. *Am. J. Clin. Nutr.* 2012; 95: 283-9.
- Maheshwari A, Paul JT. Cryptogenic cirrhosis and NAFLD: are they related? *Am J Gastroenterol* 2006; 101:664-668.

- Malviya N, Jain S, Malviya S. Antidiabetic potential of medicinal plants. *Acta poloniae pharmaceutica drug Research* 2010; 67 (2): 113-118.
- Mamun-or-Rashid ANM, Hossain MS, Hassan N, Dash BK, Sapon MA, Sen MK. A review on medicinal plants with antidiabetic activity. *Journal of Pharmacognosy and Phytochemistry* 2014; 3(4): 149-159.
- Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. *Hepatology* 2010; 51: 2229; author reply 2230.
- Manjrekar PN, Jolly CI, Narayanan S. Comparative studies of the immunomodulatory activity of *Tinospora cordifolia* and *Tinospora sinensis*. *Fitoterapia*. 2000; 71: 254-7.
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003; 37: 917-923.
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. *Lancet*. 2001;358:893-4.
- Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 1999;107:450-55.
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001;50(8):1844-50.
- Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. *J Clin Endocrinol Metab* 2008;93: Suppl 1:S74-S80.
- Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. *Curr Opin Lipidol* 2005; 16: 421-27.
- Marchesini G, Marzocchi R. MetS and NASH. *Clin Liver Dis* 2007; 11: 105-17.
- Marchetti P, Bugliani M, Boggi U, Masini M, Marselli L. The pancreatic beta cells in human type 2 diabetes. *Adv Exp Med Biol* 2012; 771: 288-309.
- Marco RD, Locatelli F, Zoppini G, Verlato G, Bonora E, M Muggeo M. Cause -Specific Mortality in Type 2 Diabetes- The Verona Diabetes Study. *Diabetes Care* 1999;22:756-61.
- Marjorie C. Plant products as antimicrobial agents. *Clinical Microbiol. Rev* 1996; 12: 564-582.
- Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. *J Hepatol* 2005;42:218-24.
- Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. *Hepatology* 2002; 36 (6): 1349-1354.
- Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. *Nutr. Rev.* 2012; 70: 41-56.
- Mathew M, Ali R, Kumar P. Intensive insulin therapy reduces hepatic steatosis and improves insulin secretion in T2DM [abstract]. *Diabetes* 2009; 58 (Suppl 1).
- Mathew PT, Augusti KT. Hypoglycemic effects of onion, *Allium cepa* Linn, on diabetes mellitus- apreliminary report. *Ind J Physiol Pharmacol* 1975; 19: 213-217.
- Matikainen N, Mänttari S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-Järvinen H, Taskinen MR. Postprandial lipemia associates with liver fat content. *Journal of Clinical Endocrinology and Metabolism* 2007; 92 (8): 3052-3059.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;116:1413-1419.
- Maurya R, Dhar KL, Handa, SS. A sesquiterpene glucoside from *Tinospora cordifolia*. *Phytochemistry*. 1997; 44: 749-50.
- Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data. *International Journal of Endocrinology* 2013; Article ID 450639:1-8.
- Maxwell JD, Sanderson I, Butler WH, Gazet JC, Pilkington TR. Hepatic structure and function after modified jejunoileal bypass surgery for obesity. *Br Med J*. 1977;2:726-729.
- Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. *Exp Diabetes Res* 2012; 2012: 716404.
- Mazzone T, Chait A, Plutzky J. Addressing cardiovascular risk in diabetes: insights from mechanistic studies. *Lancet* 2008; 24(371): 1800-9.

- MacDonald RA. Pathogenesis of nutritional cirrhosis. *Arch Intern Med* 1962;110:424–434.
- McAnlis GT, McEneny J, Pearce J, Young IS. Absorption and antioxidant effects of quercetin from onions, in man. *Eur J Clin Nutr*. 1999;53:92–96.
- McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. *J Acad Nutr Diet* 2012; 112: 401-409.
- McCullough AJ. The clinical features, diagnosis and natural history of non-alcoholic fatty liver disease. *Clin Liver Dis* 2004;8(3):521–33, viii.
- McCullough AJ. Pathophysiology of non-alcoholic steatohepatitis. *J Clin Gastroenterol* 2006;40(Suppl 1):S17–29.
- McCullough AJ. Update on nonalcoholic fatty liver disease. *J Clin Gastroenterol*, 2002;34:255–62.
- McKeown NM, Yoshida M, Shea MK, Jacques PF, Lichtenstein AH, Rogers G, Booth SL, Saltzman E. Whole-grain intake and cereal fiber are associated with lower abdominal adiposity in older adults. *J Nutr* 2009; 139: 1950-1955.
- Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. *Diabetes Care* 2004; 27:2057-2066.
- Medina-Santillan R, Lopez-Velazquez JA, Chavez-Tapia N, Torres-Villalobos G, Uribe M, Mendez-Sanchez N. Hepatic manifestations of metabolic syndrome. *Diabetes Metab. Res. Rev.* 2013, doi:10.1002/dmrr.2410.
- Medina-Campos ON, Barrera D, Segoviano-Murillo S, Rocha D, Maldonado PD, Mendoza-Patino N, Pedraza-Chaverri J. S-allylcysteine scavenges singlet oxygen and hypochlorous acid and protects LLC-PK(1) cells of potassium dichromate-induced toxicity. *Food Chem Toxicol*. 2007;45:2030–9.
- Mehta R, Younossi ZM. Natural History of Nonalcoholic Fatty Liver Disease. *Clinical Liver Disease* 2012; 1 (4): 112-113.
- Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. *World J Gastroenterol* 2008; 14: 3476-3483.
- Melanson KJ, Westerterp-Plantenga MS, Saris WH, Smith FJ, Campfield LA. Blood glucose patterns and appetite in time-blinded humans: carbohydrate versus fat. *Am J Physiol* 1999; 277: R337-R345.
- Mentreddy SR, Mohamed AI, Rimando AM. Medicinal plants with hypoglycemic/anti-hyperglycemic properties: a review. *Proc Assoc Adv Ind Crop Conf* 2005; 20:341-353.
- Merat S, Yarahmadi S, Tahaghoghi S, Alizadeh Z, Sedighi N, Mansournia N, Ghorbani A, Malekzadeh R. Prevalence of Fatty Liver Disease among Type 2 Diabetes Mellitus Patients and its Relation to Insulin Resistance. *Middle East Journal of Digestive Diseases* 2009; 1 (2): 74-79.
- Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected non-alcoholic fatty liver disease. *Hepatology* 2006;44(4):874–80.
- Micha R, Mozaffarian D. Trans fatty acids: Effects on metabolic syndrome, heart disease and diabetes. *Nat Rev Endocrinol* 2009;5:335–344.
- Miani M, Barthson J, Colli ML, Brozzi F, Cnop M, Eizirik DL. Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1 β -induced apoptosis via Bim/A1 imbalance. *Cell Death Dis* 2013; 4: e701
- Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, Masana L, Mangas A, Hernández-Mijares A, González-Santos P, Ascaso JF, Pedro-Botet J. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. *Vascular Health and Risk Management* 2009;5 757–765.
- Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids – a promising novel therapy for non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2010;31:679–692.
- Miller ER, Pastor-Barriuso R, Dalal D, Riemersmara, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142:37-46.
- Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. *Cell Metab*. 2012; 15: 665–74.

- Misra A, Vikram NK, Gupta R, Pandey RM, Wasir JS, Gupta VP. Waist circumference cutoff points and action levels for Asian Indians for identification of abdominal obesity. *Int. J. Obes.* 2006; 30: 106–111.
- Misra A, Shrivastava U. Review Obesity and Dyslipidemia in South Asians. *Nutrients* 2013; 5: 2708-2733.
- Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: Continuing escalation & possible solutions. *Indian J Med Res* 2007; 125: 345-354.
- Mittal J, Sharma MM, Batra A. *Tinospora cordifolia*: a multipurpose medicinal plant- A Review. *Journal of Medicinal Plants Studies* 2014; 2 (2): 32-47.
- Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TPA. Indian herbs and herbal drugs used for the treatment of diabetes. *Journal of Clinical Biochemistry and Nutrition* 2007; 40: 163-173.
- Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. *Hepatology* 2003;37:1286-92.
- Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. *Diabetes Res Clin Pract.* 2009;84:84–91.
- Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology* 2012; 55: 429–36.
- Montesi L, Caselli C, Centis E, Nuccitelli C, Moscattello S, Suppini A, Marchesini G. Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? *World J Gastroenterol* 2014; 20: 10128-10136.
- Montonen J, Jarvinen R, Knekt P, Heliovaara M, Reunanen A. Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. *J. Nutr.* 2007; 137: 1447–1454.
- Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. *Obes Res* 2003; 11:1048-54.
- Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia* 2001;44 Suppl 2:S14–S21.
- Moscattello S, Di Luzio R, Bugianesi E, Suppini A, Hickman IJ, Di Domizio S, Dalle Grave R, Marchesini G. Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study. *Obesity (Silver Spring).* 2011;19(4):763-70.
- Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. *Obesity Surgery* 2004; 14 (5): 635–637.
- Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. *J. Clin. Gastroenterol.* 2012; 46: 457–67.
- Moyer VA. U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. *Ann. Intern. Med.* 2012; 157: 373–8.
- Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall H-U, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology.* 2013; 145: 574-582.
- Mullaicharam AR, Deori G, Maheswari UR. Medicinal Values of Fenugreek – A Review. *Research Journal of Pharmaceutical, Biological and Chemical Sciences* 2013;4(1):1304- 1313.
- Mummadi RR, Kasturi KS, Chennareddygar S, Sood GK. Effect bariatric surgery on nonalcoholic liver disease: systematic review and metaanalysis. *Clin gastroenterol hepatol* 2008; 6: 1396-402.
- Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology.* 2010;52(1):79-104.
- Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003; 37: 909-916.

- Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012; 55: 885-904.
- Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwittaya P, George J, Barrera F, Häflödóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. *PLoS Med* 2014; 11(7): e1001680:1-26.
- Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology*. 2010;52(1):79-104.
- Myers VH, Mcvay MA, Brashear MM, Johannsen NM, Swift DL, Kramer K, Harris MN, Johnson WD, Earnest CP, Church TS. Exercise Training and Quality of Life in Individuals With Type 2 Diabetes A randomized controlled trial. *Diabetes Care*. 2013 Jul;36(7):1884-90.
- Nagaraja PK, Kammar KF, Sheela DR. Efficacy of *Tinospora cordifolia* (Willd.) extracts on blood lipid profile in streptozotocin diabetic rats. Is it beneficial to the heart? *Biomed Res* 2008; 19: 92-96.
- Nagpal J, Kumar A, Kakar S, Bhartia A. The development of quality of life instrument for Indian diabetes patients (QOLID): a validation and reliability study in middle and higher income groups. *J Assoc Physicians India* 2010; 58: 295-304.
- Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. *Aliment Pharmacol Ther*. 2004;20:23-8.
- Nandaa UK. Clinical evaluation of non-hormonal drug 'minofil' in the management of post menopausal syndrome, *Maturitas* 1997; 27(1): 215.
- Nandakumar S, Mani UV, Mani I. An Open Label Study on the Supplementation of *Gymnema sylvestre* in Type 2 Diabetics. *Journal of dietary supplements* 2010; 7 (3): 273-282.
- Nasreen S, Radha R, Jayashree N, Selvaraj B, Rajendran A. Assessment Of Quality Of *Tinospora Cordifolia* (Willd.) Miers. (Menispermaceae): Pharmacognostical And Phyto - Physicochemical Profile. *Pharmacie Globale (IJCP)* 2010; 1 (5): 1-4.
- Nazarenko LI, Petrova Iu N, Raikhel'son KL, Baranovskii A. [Nutrition mistakes in patients with nonalcoholic fatty liver disease and the ways of correction]. *Eksp Klin Gastroenterol*. 2012(2):19–24.
- Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA* 2001, 285, 2486–2497.
- Nakamuta M, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Enjoji M. Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. *Int J Mol Med* 2009; 23: 603-608.
- Nakamuta M, Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Yada M, Yada R, Takemoto R, Fukuizumi K, Harada N, Taketomi A, Maehara Y, Nakashima M, Enjoji M. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. *Int J Mol Med* 2008; 22: 663-667.
- Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S, Yoshimitsu K, Enjoji M, Kotoh K, Taketomi A, Uchiyama H, Shimada M, Nawata H, Maehara Y Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. *Transplantation* 2005; 80: 608-612.
- Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I, Enjoji M. Evaluation of fatty acid metabolism related gene expression in nonalcoholic fatty liver disease. *Int J Mol Med* 2005; 16: 631-635.
- Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. *Clin Biochem*. 2010; 43(10-11):815-21.
- NHANES Laboratory procedure manual, Hepatitis B surface antigen in serum NHANES 2011-2012.

- NHANES Laboratory procedure manual, Assay for Antibody to Hepatitis C Virus(Ortho) and Confirmatory Chiron RIBA in Serum, 2007-2008.
- NHANES Laboratory procedure manual, Complete blood count, 2007-2008.
- NHANES Laboratory procedure manual, C-Reactive Protein in Serum, 2007-2008.
- NHANES Laboratory procedure manual, Iron in Refrigerated Serum, 2006-2006.
- NHANES Laboratory procedure manual, Ferritin in serum, 2009-2010.
- NHANES Laboratory procedure manual, Blood Urea Nitrogen (BUN) in Refrigerated Serum, 2006-2006.
- NHANES Laboratory procedure manual, Creatinine in Refrigerated Serum, 2001-2002.
- NHANES Laboratory procedure manual, Uric Acid in Refrigerated Serum, 2011-2012.
- NHANES Laboratory procedure manual, Total Cholesterol, Direct HDL, Precipitated HDL, Triglycerides, and LDL, 2003-2004.
- NHANES Laboratory procedure manual, Gamma-Glutamyl Transferase (GGT), 2007-2008.
- NHANES Laboratory procedure manual, Free T3 (FT3) in Serum, 2011-2012.
- NHANES Laboratory procedure manual, Free Thyroxine (Free T4) in Serum, 2007-2008
- NHANES Laboratory procedure manual, Thyroid Stimulating Hormone, 2001-2002
- NHANES Laboratory procedure manual, 25-Hydroxyvitamin D in Serum, 2001-2002
- NHANES Laboratory procedure manual, Glycohemoglobin in Whole Blood, 2007-2008
- Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology*. 2003;38: 1008-17.
- Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 2003, 37: 1202-1219.
- Nichols TW. A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy. *J Liver* 2013; 3 (1): 144: 1-12.
- Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. *J Nutr Biochem* 2012;23:203-208.
- Mcavoy NC, Ferguson JW, Campbell IW and Hayes PC. Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. *British Journal of Diabetes & Vascular Disease* 2006; 6: 251-60.
- Nouredin M, Loomba R. Nonalcoholic Fatty Liver Disease: Indications for Liver Biopsy and Noninvasive Biomarkers. *Clinical Liver Disease* 2012;1:(4): 104-107.
- Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. *Fibrogenesis Tissue Repair* 2008; 1, 5, doi:10.1186/1755-1536-1-5.
- Nseir W, Nassar F, Assy N. Soft drinks consumption and non-alcoholic fatty liver disease. *World J Gastroenterol* 2010; 16(21): 2579-2588.
- Obika M, Noguchi H. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. *Experimental Diabetes Research*. 2012; 1-12.
- Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O'Sullivan TA, Ayonrinde OT, Olynyk JK, Black LJ, Beilin LJ, Mori TA, Hands BP, Adams LA. The western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. *Am. J. Gastroenterol*. 2013; 108: 778-785.
- Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008; 28: 503-522.
- Okwu DE. Phytochemicals and vitamin content of indigenous species of southeastern Nigeria. *J.Sustain Agric. Environ* 2004; 6(1): 30-37.
- Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Predictors of non-alcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. *Obes Surg* 2005;15(3): 310-5.
- Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008;49:608-612.
- Ong J, Younossi ZM. Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. Editorial. *Am J Gastroenterol* 2010; 105: 621-623.
- Onkar P, Bangar J, Karodi R. Evaluation of Antioxidant activity of traditional formulation Giloy satva and hydroalcoholic extract of the *Curculigo orchoides* gaertn. *Journal of Applied Pharmaceutical Science*, 2012; 02 (06): 209-13.

- Oprea-Călin G, Babeş PA, Andronescu DV, Crăița-Isabela Andronescu. Connection between non-alcoholic fatty liver disease and diabetes mellitus. *Romanian Journal of Diabetes Nutrition and Metabolic Diseases* 2014; 21 (2):121–127.
- Otsuka R, Tamakoshi K, Yatsuya H, Murata C, Sekiya A, Wada K, Zhang HM, Matsushita K, Sugiura K, Takefuji S, OuYang P, Nagasawa N, Kondo T, Sasaki S, Toyoshima H. Eating fast leads to obesity: findings based on self-administered questionnaires among middle-aged Japanese men and women. *J Epidemiol* 2006; 16: 117-124.
- Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol* 2008; 48: 993-999.
- Padmapriya S, Kumanan K, Rajamani K. Optimization of post harvest techniques for *Tinospora cordifolia*. *Academic Journal of Plant Sciences*. 2009; 2: 128-31.
- Pai S, Madi DR, Achappa B, Unnikrishnan. Non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. *Int J Biol Med Res*. 2012; 3 (3): 2189-2192.
- Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. *Clin Res Hepatol Gastroenterol* 2011; 35: 23–28.
- Pagadala M, Zein CO, McCullough AJ. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. *Clin Liver Dis* 2009; 13: 591–606.
- Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology* 2002; 35: 367-372.
- Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing non-alcoholic steatohepatitis from simple steatosis in patients with non-alcoholic fatty liver disease. *Liver Int* 2006;26(2):151–6.
- Pandey MM, Rastogi S, Rawat AKS. Indian Traditional Ayurvedic System of Medicine and Nutritional Supplementation. Evidence-Based Complementary and Alternative Medicine Volume 2013; Article ID 376327: 12 pages.
- Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. *Journal of Clinical Gastroenterology*. 2006; 40 (7): 633–635.
- Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. *World J Hepatol* 2015; 7(3): 575-582.
- Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. *J Korean Med Sci*. 1995;10:414-421.
- Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, Ha HK, Lee MG, Hwang S, Lee SG, Yu ES, Cho EY. Macrovesicular hepatic steatosis in living liver donors: Use of CT for quantitative and qualitative assessment. *Radiology* 2006;239:105-12.
- Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. *J Gastroenterol Hepatol* 2007;22(4):491–7.
- Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J. Hepatol*. 2012; 56: 944–51.
- Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. *Liver Int* 2012; 32: 701-711.
- Parveen TD, Nyamathulla S. Antihyperlipidemic Activity of the Methanolic extract from the Stems of *Tinospora cordifolia* on Sprague dawley rats. *Der Pharmacia Sinica* 2011; 2 (1): 104-109.
- Patel MB, Mishra S. Hypoglycemic activity of alkaloidal fraction of *T. cordifolia*. *Phytomedicine*. 2011; 18: 1045-52.
- Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2015; 13: 561-568.e1.
- Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids. *Journal of Nutrition and Metabolism*; 2012; Article ID 539426, 16 pages.

- Patwardhan B. The quest for evidence-based Ayurveda: lessons learned. *Curr Sci* 2012; 102(10): 1406-1417.
- Pearson TA, Mensah GA, Alexander W, Anderson JL, Cannon, III RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith, Jr SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003;107:499-511.
- Pendse VK, Dadhich AP, Mathur PN, Bal MS. Antiinflammatory, immunosuppressive and some related pharmacological actions of the water extract of Neem Giloe (*Tinospora cordifolia*): A preliminary report *Indian J Pharm*,1977, 9, 221- 4.
- Perlemuter G, Bigorgne A, Cassard-Doulcier A-M, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. *Nature Clinical Practice* 2007;3:458–69.
- Perri MG, Martin AD, Leermakers EA, Sears SF, Notelovitz M. Effects of group- versus home-based exercise in the treatment of obesity. *J Consult Clin Psychol* 1997;65:278-285.
- Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. *Diab Care* 2009; 32[Suppl. 2]: S164–S167.
- Perseghin G, Lattuada G, DeCobelli F, Ragogna F, Ntali G, Esposito A, Belloni E, Canu T, Terruzzi I, Scifo P, Del Maschio A, Luzi L. Habitual physical activity is associated with intrahepatic fat content in humans. *Diabetes Care* 2007; 30 (3): 683–688.
- Perseghin G, Mazzaferro V, Sereni LP, Regalia E, Benedini S, Bazzigaluppi E, Pulvirenti A, Leão AA, Calori G, Romito R, Baratti D, Luzi L. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. *Hepatology* 2000; 31(3):694-703.
- Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. *Dig Dis* 2010; 28: 210–213.
- Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of non-alcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005;54:603–8.
- Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemanly L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci U S A* 2007;104:12587-94.
- Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla MC, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc Natl Acad Sci U S A* 2006;103:18273-7.
- Petersen KF, Shulman GI. Etiology of insulin resistance. *Am. J. Med.* 2006; 119 (5 Suppl. 1): S10–16.
- Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, Maluenda F, Diaz JC, Rencoret G, Braghetto I, Castillo J, Poniachik J, Videla LA. Enhancement in liver srebp-1c/ppar- α ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. *Biochim. Biophys. Acta* 2009; 1792: 1080–1086.
- Pfützner A, Forst T. High-sensitivity C-reactive protein as cardio-vascular risk marker in patients with diabetes mellitus. *Diabetes Technol Ther* 2006, 8(1):28–36.
- Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. *Cell.* 2004; 119:529–542.
- Phillips G, Barton A. Diet Therapies for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Style Review. *European Journal of Nutrition & Food Safety* 4(3): 189-190, 2014.
- Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: oneyear results of the look AHEAD trial. *Diabetes Care* 2007;30:1374–1383.

- Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. *Diabetes Care* 2011;34:1369–71.
- Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2007;92(6):2017–29.
- Pollock NK, Bundy V, Kanto W, Davis CL, Bernard PJ, Zhu H, Gutin B, Dong Y. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. *J Nutr* 2012; 142: 251-257.
- Porchezian E, Dobriyal R.M. An overview on the advances of *Gymnema sylvestre*: Chemistry, pharmacology and patents. *Pharmazie*. 2003;58:5–12.
- Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. *Diabetes Metab* 2008;34: 643–648.
- Powell EE, Jonsson JR, Clouston AD. Dangerous Liaisons: The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. *Ann Intern Med*. 2005;143:753-754.
- Prabhakar PK, Doble M. Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes. *Phytomedicine* 2009; 16(12): 1119-1126.
- Prakash S, Rai NP. Role of *Tinospora cordifolia* (Willd.) Miers (Guduchi) in the treatment of infective hepatitis. *J Res Ayurv Siddha* 1996;17 (1-2)58.
- Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, Menon PS, Shah NS. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. *JAPI* 2009; 57:205-10.
- Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; 51: 121-129.
- Purandare H, Supe A. Immunomodulatory role of *Tinospora cordifolia* as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study. *Indian Journal of Medical Sciences*. 2007; 61: 347-55.
- Puranik N, Kammar KF, Devi S. Modulation of morphology and some gluconeogenic enzymes activity by *Tinospora cordifolia* (Willd.) in diabetic rat kidney. *Biomedical Research* 2007; 18 (3): 179-183.
- Puranik N, Kammar KF, Devi S. Anti-diabetic activity of *Tinospora cordifolia* (Willd.) in streptozotocin diabetic rats; does it act like sulfonylureas?. *Turk J Med Sci* 2010; 40 (2): 265-270.
- Puri P, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup. *Clinical Liver Disease* 2012; 1 (4): 99-103.
- Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. *Am J Cardiol*. 2003;91(Suppl):20C–24C.
- Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Longterm follow-up of patients with non-alcoholic fatty liver. *Clin Gastroenterol Hepatol* 2009;7:234-238.
- Raghunathan K, Mitra R. *Pharmacognosy of Indigenous Drugs*. New delhi; Central Council for Research in Ayurvedic and Siddha; 1982.
- Rai M, Gupta SS. The deposition of the secondary salts over the five pellets in rats was inhibited by the aqueous extract of *T. cordifolia*. *J Res Ind Med*; 1966: 10, 113-6.
- Rajalakshmi M, Eliza J, Priya CE, Nirmala A, Daisy P. Anti-diabetic properties of *Tinospora cordifolia* stem extracts on streptozotocin- induced diabetic rats. *Afr. J. Pharm. Pharmacol* 2009; 3(5): 171-180.
- Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. *World J Gastroenterol* 2009; 15: 4770–4774.
- Rana V, Thakur K, Sood R, Sharma V, Sharma TR. Genetic diversity analysis of *Tinospora cordifolia* germplasm collected from northwestern Himalayan region of India. *J. Genet* 2012; 91: 99-103.
- Ratzliff V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. *Gastroenterology* 2000;118(6):1117–23.

- Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T; LIDO Study Group. Sampling variability of liver biopsy in non-alcoholic fatty liver disease. *Gastroenterology* 2005;128(7):1898–906.
- Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology* 2008;135:100–110.
- Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, LeNaour G, Hartemann-Heurtier A, Bruckert E and Poynard T for the LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. *HEPATOLOGY* 2010;51:445–453.
- Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010; 53: 372–384.
- Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology*. 2002;35:1485–93.
- Rawat M, Parmar N. Medicinal Plants with Antidiabetic Potential - A Review. *American-Eurasian J. Agric. & Environ. Sci* 2013; 13 (1): 81–94.
- Raz I, Eldor R, Cernea S, Shafir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. *Diabetes Metab Res*. 2005; 21: 3–14.
- Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. *World J Gastroenterol* 2008; 14 (2): 185–192.
- Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal β -oxidation, PPAR- α , and steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 2001; 281: G1333–G1339.
- Ridker PM. High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. *Circulation*. 2001;103:1813–1818.
- Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: A systematic review and meta-analysis. *BMC Cardiovasc Disord*. 2008;8:13.
- Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. *J Am Diet Assoc* 2009; 109: 668–679.
- Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. *Gastroenterology & Hepatology* 2014; 10 (4): 219–227.
- Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. *J Hum Nutr Diet* 2005; 18: 365–370.
- Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. *Nat Clin Pract Endocrinol Metab* 2006; 2: 335–348.
- Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care* 2005; 28(9):2130–2135.
- Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Méndez-Sánchez N. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. *Annals of Hepatology* 2008; 7(3): 212–220.
- Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of non alcoholic steatohepatitis. *Free Radic Biol Med* 2012; 52: 59–69.
- Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of non-alcoholic Fatty liver disease. *Int J Endocrinol* 2013; 2013: 585876.
- Roy K and Iyer U. Quality of life of type 2 diabetes patients with newly diagnosed non-alcoholic fatty liver disease using quality of life instrument for Indian diabetes patients. *Journal Of Social Health and Diabetes* 2014; 2: 87–91.
- Roy K, Shah R and Iyer U. *Tinospora cordifolia* stem supplementation in diabetic dyslipidemia: an open labelled randomized controlled trial. *Functional Foods in Health and Disease* 2015; 5(7): 265–274.

- Rubin RR and Peyrot M. Quality of Life and Diabetes. *Diabetes Metab Res Rev.* 1999; 15: 205-218.
- Ruderman N, Prentki M. AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. *Nat Rev Drug Discov* 2004; 3: 340-351.
- Ruhl CE, Everhart JE. Epidemiology of non-alcoholic fatty liver. *Clin Liver Dis* 2004;8(3):501–19, vii.
- Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2003;124:71-79.
- Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. *Nutr Rev* 2007; 65: S13-S23.
- Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond PV, Johnson NA, Wilson AM. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol* 2013;59:138–43.
- Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with non-alcoholic fatty liver disease. *Diabetes Care* 2005;28:1222-1224.
- Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. *Liver Transplantation* 2002; 8 (12): 1114–1122.
- Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. *Diabetes*, 2000;49:749–58.
- Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002;123:745-50.
- Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, Jonge LD, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N. Engl. J. Med.* 2009; 360: 859–73.
- Saeed MK, Shahzadi I, Ahmad I, Ahmad R, Shahzad K, Ashraf M, Viqar-un-Nisa. Nutritional analysis and antioxidant activity of bitter gourd (*Momordica charantia*) from Pakistan. *Pharmacologyonline* 2010;1: 252-260.
- Saha S, Ghosh S. *Tinospora cordifolia*: One plant, many roles. *Anc Sci Life* 2012; 31(4): 151–159.
- Salas-Flores R, González-Pérez B, Echegollen-Guzmán A. Hepatic steatosis and type 2 diabetes mellitus in health workers. *Rev Med Inst Mex Seguro Soc* 2012; 50 (1): 13-18.
- Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *Journal of Biological Chemistry* 2004; 279 (31): 32345–32353.
- Sankhala LN, Saini RK and Saini BS A review on chemical and biological properties of *Tinospora cordifolia*. *IJMAP* 2012; 2(2): 340-344.
- Santos LF, Hernández G, Puerta AV, Beltrán O, Botero RC, Mejía G. Non alcoholic fatty liver disease. The new millennium pandemic 1. *Rev Col Gastroenterol* 2010; 25 (4):373-391.
- Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. *Braz J Med Biol Res* 2003; 36: 723-729.
- Santoliquido A, Di Campli C, Miele L. Hepatic steatosis and vascular disease. *Eur Rev Med Pharmacol Sci* 2005; 9: 269- 71.
- Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. *Gastroenterology.* 2002;123:1705-25.
- Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology* 2006;43:682-689.
- Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratzliff V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011;54:344–353.

- Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001;120:1183-92.
- Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; 362: 1675-1685.
- Sasaki S, Katagiri A, Tsuji T, Shimoda T, Amano K. Selfreported rate of eating correlates with body mass index in 18-y-old Japanese women. *Int J Obes Relat Metab Disord* 2003; 27: 1405-1410.
- Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients. *Diabetes Res Clin Pract* 1989; 7: 33-40.
- Sathiaraj E, Chutke M, Reddy M Y, Pratap N, Rao PN, Reddy DN, Raghunath M. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. *Eur J Clin Nutr.* 2011; 65 (4):533-537.
- Sattar N, Ewan Forrest, David Preiss. Non-alcoholic fatty liver disease. Clinical review. *BMJ.* 2014; 349: 1-8.
- Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, Gross R, Roy M, Leconte A, Gomis R, Ribes G. 4-hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. *Diabetes* 1998; 47: 206–210.
- Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiol Rev* 2007;87:507-20.
- Savage DB, Semple. RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. *Current Opinion in Lipidology* 2010; 21 (4):329–336.
- Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, D'souza S, Subramaniam A, Dhairyawan P, Todur S, Tester F. Ashavaid. Prevalence of Metabolic Syndrome in Urban India. *Cholesterol Volume* 2011, Article ID 920983, 7 pages.
- Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA* 2004, 291:335-342.
- Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. *Curr. Opin. Clin. Nutr. Metab. Care* 2012; 15: 374–80.
- Schulze MB, Manson JE, Willett WC, Hu FB. Processed meat intake and incidence of type 2 diabetes in younger and middle-aged women. *Diabetologia*, 2003, 46:1465–1473.
- Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. *J Gastroenterol Hepatol* 2013; 28 Suppl 1: 68-76.
- Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: metaanalysis of randomised controlled trials. *BMJ.* 2010;341:c5702.
- Schwenger KJP, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. *World J Gastroenterol* 2014; 20(7): 1712-1723.
- Schwenzer NF, Machann J, Martirosian P, Stefan N, Schraml C, Fritsche A, Claussen CD, Schick F. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. *Invest Radiol* 2008; 43: 330-337.
- Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. *Endocrine* 2011; 40: 332–343.
- Selvaraj, S. and Chandavar, Vidya R. and Naik, Prakash R. and Moqbel, Fahmi S. (2012) Fractions of *Tinospora cordifolia* stem extract demonstrate insulin secreting activity in diabetes induced Wistar rats. *Journal of Pharmacy Research* 2012; 5 (3): 1424-1427.
- Seo HI, Cho YK, Lee WY, Rhee EJ, Sung KC, Kim BS, Son BH, Shin JH, Joo KJ, Hong HP, Chae SW, Jin W. Which metabolic syndrome criteria best predict the presence of nonalcoholic fatty liver disease? *Diabetes Res Clin Pract* 2012; 95: 19–24.
- Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. *Diabetes Metab* 2008; 34: 634-637.
- Serrano-Martinez M, Palacios M, Martinez-Losa E, Lezaun R, Maravi C, Prado M, Martínez JA, Martinez-Gonzalez MA. A Mediterranean dietary style influences TNF-alpha and VCAM-1 coronary blood levels in unstable angina patients. *Eur J Nutr.* 2005;44(6):348–54.
- Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in

- men: the Physicians' Health Study II randomized controlled trial. *JAMA* 2008; 300: 2123-2133.
- Seth, SD, Sharma B. Medicinal plants of India. *Indian J. Med. Res.* 2004; 120: 9–11.
 - Shah GL. Some economically important plants of salsette island near Bombay. *Journal of Economic and Taxonomic Botany.* 1984; 5: 753-6.
 - Shah GL, Yadav SS, Badari N. Medicinal plants from Dahanu forest division in Maharashtra state. *Journal of Economic and Taxonomic Botany.* 1983; 5: 141-4.
 - Shams M, Baraka E. Measuring the Rate of Therapeutic Adherence among Outpatients with T2DM in Egypt. *Saudi Pharm J.* 2010; 18: 225–232. doi:10.1016/j.jsps.2010.07.004
 - Shams MEE, Al-Gayyar MMH, Barakat EAME. Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. *Sci Pharm.* 2011; 79: 623–634.
 - Shankarappa L, Gopalakrishna B, Jagadish NR, Siddalingappa GS. Pharmacognostic and phytochemical analysis of *Costus ignitius*. *Internationale Pharmaceutica Scientia.* 2011;1:36–41.
 - Sharma R, Amin H, Galib, Prajapati PK. Antidiabetic claims of *Tinospora cordifolia* (Willd.) Miers: critical appraisal and role in therapy *Asian Pac J Trop Biomed* 2015; 5(1): 68-78.
 - Sharma D, Singh SK. Status of Liver Enzymes in Non Alcoholic Fatty Liver in Obese Type-2 Diabetic Subjects. *International Journal of Science and Research* 2014; 3 (7):1652-1653.
 - Sharma D, Singh SK, Gupta P, Singh N, Singh N. Role of Insulin Resistance in Non Alcoholic Fatty Liver in Obese Type-2 Diabetic Subjects. *JMSCR* 2014;2 (7): 1838-1843.
 - Sharma A, Batra A. Berberine a novel antidiabetic drug. *Int J Res Rev Pharm Appl Sci* 2013; 3(2): 216-230.
 - Sharma, A., Gupta A, Singh S, Batra A. *Tinospora cordifolia* (Willd.) Hook. F. and Thomson - A plant with immense economic potential. *Journal of Chemical and Pharmaceutical Research* 2010; 2: 327-33.
 - Sharma R, Sinha S, Danishad KA, Vikram NK, Gupta A, Ahuja V, Jagannathan NR, Pandey RM, Misra A. Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo (31P) phosphorus magnetic resonance spectroscopy. *Atherosclerosis* 2009; 203: 291–297.
 - Sharma RD, Raghuram TC. Hypoglycaemic effect of fenugreek seeds in non-insulin dependent diabetic subjects. *Nutr Res* 1990;10:731–739.
 - Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulfoxide isolated from garlic *Allium sativum* Linn. *Indian J. Exp. Biol.*, 30, 523–526, 1992.
 - Shetty AJ, Parampalli SM, Bhandarkar R, Kotian S. Effect of the insulin plant (*Costus igneus*) leaves on blood glucose levels in diabetic patients: A cross sectional study. *J Clin Diagn Res.* 2010;4:2617–21.
 - Shimizu C, Kihara M, Aoe S, Araki S, Ito K, Hayashi K, Watari J, Sakata Y, Ikegami S. Effect of high beta-glucan barley on serum cholesterol concentrations and visceral fat area in Japanese men—a randomized, doubleblinded, placebo-controlled trial. *Plant Foods Hum Nutr* 2008; 63: 21–25.
 - Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological and biochemical considerations. *Pathol Annu* 1989;24:275-302.
 - Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF. Liver pathology in morbidly obese patients with and without diabetes. *Am J Gastroenterol* 1990;85: 1349-55.
 - Simons FE, Rhinitis: recent advances. *Pediatr Clin North Am* 1988;35 (3): 1053-74.
 - Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, McCurdy H, Marrero JA. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. *J Clin Gastroenterol* 2011;45: 727–32.
 - Singh AK, Kumar A, Haque SF. Nonalcoholic Fatty Liver Disease: Evidence based management. *Int J Biol Med Res.* 2015;6(2):5035-5042.
 - Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. *Dig Dis Sci* 2008;53(7):1967–76.
 - Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. *Indian J Endocr Metab* 2013;17:990-5.

- Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, Rao M. Prevalence of non-alcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. *Indian J Gastroenterol*. 2004;25:76–9.
- Singh KK, Maheshwari JK. Traditional phytotherapy amongst the tribals of Varanasi district U.P. *Journal of Economic and Taxonomic Botany*. 1983; 4: 829-32.
- Singh SS, Pandey SC, Srivastava S, Gupta VS, Patro B, Ghosh AC. Chemistry and medicinal properties of *Tinospora cordifolia* (Guduchi). *Indian Journal of Pharmacology*. 2003; 35: 83-91.
- Singh KP, Gupta AS, Pendse VK, Mahatma CP, Bhandari DS, Mahawar MM. Experimental and clinical studies on *Tinospora cordifolia*. *J Res Indian Med*. 1975;10:9–14.
- Sinha K, Mishra NP, Singh J, Khanuja SPS. *Tinospora cordifolia* (Guduchi), a reservoir plant for therapeutic applications: A review. *Indian Journal of Traditional Knowledge*. 2004; 3: 257-70.
- Skevington S.M., Lotfy M, O’Connell K.A. The World Health Organisation’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHO QOL Group. *Quality of Life Research*. 2004;13: 299-310.
- Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. *Eur Rev Med Pharmacol Sci*. 2005;9:291-3.
- Smirnov IM, Bailey K, Flowers CH, Garrigues NW, Wesselius LJ. Effects of TNF-alpha and IL-1beta on iron metabolism by A549 cells and influence on cytotoxicity. *Am J Physiol*. 1999; 277:L257–L263.
- Smith BW, Adams LA. Non-alcoholic fatty liver disease. *Crit Rev Clin Lab Sci* 2011; 48: 97-113.
- Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. *Nature Reviews Endocrinology* 2011; 7 (8): 456–465.
- Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. *Ann Intern Med* 2001; 135: 447-459.
- Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 2010; 51: 595-602.
- Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. *J Clin Gastroenterol* 2008; 42: 1117-1119.
- Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T. Dietary composition and nonalcoholic fatty liver disease. *Dig Dis Sci* 2004; 49: 1578-1583.
- Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M, Kashyap SR, Watanabe RM, Barkoukis H, Kirwan JP. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. *Am J Clin Nutr*. 2010;92(6): 1359-1368.
- Somalwar AM, Raut AD. Study of association of non alcoholic fatty liver disease (NAFLD) with micro and macrovascular complications of type 2 diabetes mellitus (T2DM). *Int J Res Med Sci*. 2014;2(2):493-497.
- Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. *J Hepatol* 2008;49:600-7.
- Spelman K. Traditional and clinical uses of *Tinospora cordifolia*, guduchi. *Aust J Med Herbalism*. 2001;13:49–57.
- Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R. Silent non-alcoholic fatty liver disease- a clinical-histological study. *J Hepatol* 2004; 41: 751–7.
- Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. *Dig. Liver Dis* 2008; 40: 194–199.
- Spahn JM, Reeves RS, Keim KS, Laquatra I, Kellogg M, Jortberg B, Clark NA. State of the evidence regarding behavior change theories and strategies in nutrition counseling to facilitate health and food behavior change. *J. Am. Diet. Assoc*. 2010; 110: 879–891.
- Spruss A, Bergheim I. Dietary fructose and intestinal barrier: Potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. *J Nutr Biochem* 2009;20:657–662.

- Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. *J Gastroenterol Hepatol*. 2006;21:191-198.
- Srinivasan K. Fenugreek (*trigonella foenum-graecum*): A review of health beneficial physiological effects. *Food Rev Internat*. 2006;22:203–24.
- Srivastava, P. *Tinospora cordifolia* (Amrita)- A miracle herb and lifeline to many diseases. *International Journal of Medicinal and Aromatic Plants* 2011; 1(2): 57-61.
- Stancu C, Sima A. Statins: mechanism of action and effects. *Journal of Cellular and Molecular Medicine* 2001; 5 (4): 378-387.
- Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beyesen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/ obese humans. *J Clin Invest* 2009;119:1322–1334.
- Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. *Endocr Rev* 2008;29:939-60.
- St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 2009;50:68–76.
- Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. *Drug Alcohol Depend* 2001;61:211–15.
- Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. *Gut* 2010;59:1410-1415.
- Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006;43:1317-1325.
- St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. *J Gastroenterol Hepatol* 2009; 24: 399-407.
- Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications *Gut* 2010;59:10 1303-1307.
- Sudha P, Smitha SZ, Shabha YB, Ameeta RK. Potent α -amylase inhibitory activity of Indian Ayurvedic medicinal plants. *BMC Complement Altern Med*. 2011; 11: 1-10.
- Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* 2002; 106 (15): 1943–1948.
- Sullivan S. Implications of diet on nonalcoholic fatty liver disease. *Curr Opin Gastroenterol* 2010;26:160–164.
- Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. *Hepatology Research* 2009; 39 (3): 213–222.
- Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, Yoshikawa T. Long-term efficacy of vitamin E for non-alcoholic steatohepatitis. *Hepatogastroenterology* 2013; 60: 1445-1450.
- Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. *Diabetes Care* 2012;35:717-22.
- Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. *Atherosclerosis* 2009;203:581–586.
- Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. *J. Hepatol*. 2005; 43: 1060–1066.
- Swart GR, Zillikens MC, Van Vuure JK, Van den Berg JWO. Effect of a late evening meal on nitrogen balance. in patients with cirrhosis of the liver,” *BritishMedical Journal* 1989; 299 (6709): 1202–1203.

- Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by ¹H spectroscopy: validation in vivo. *Am J Physiol* 1999; 276: E977-E989.
- Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 2005;288:E462–E468.
- Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? *J Gastroenterol Hepatol*. 2011; 26: 501-509.
- Tahaei SA, Sedighi N, Derogar R, Aslani A, Malekzadeh R, Merat S. The Effect of Weight Reduction on Ultrasonographic Findings of Nonalcoholic Fatty Liver. *Middle East Journal of Digestive Diseases* 2010; 2 (1):5-8.
- Tahan V, Canbakan B, Balci H, Dane F, Akin H, Can G, Hatemi I, Olgac V, Sonsuz A, Ozbay G, Yurdakul I, Senturk H. Serum gammaglutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. *Hepato-Gastroenterology* 2008; 55 (85): 1433–1438.
- Takuma Y, Nouse K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. *World J Gastroenterol*. 2010;16:1436-41.
- Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. *J Clin Endocrinol Metab* 2005;90:3191–6.
- Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. *J. Clin. Gastroenterol*. 2008; 42: 413–418.
- Tangvarasittichai S, Poonsub P, Tangvarasittichai O. Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. *Indian J Med Res* 2010; 131: 641-648.
- Tarantino G, Saldalamacchia G, Conca P and Arena A. Non-alcoholic fatty liver disease: Further expression of the metabolic syndrome. *Journal of Gastroenterology and Hepatology* 2007; 22: 293–303.
- Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increase of cardiovascular events in type 2 diabetic patients. *Diabetes Care*, 2007; 30: 2119–21.
- Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutr. Metab. Cardiovasc. Dis.* 2007; 17: 517–524.
- Targher G. Nonalcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. *Diabet Med* 2007; 24:1–6.
- Takeuchi Y, Ito H, Komatsu Y, Oshikiri K, Antoku S, Abe M, Mifune M, Togane M. Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients: a cross-sectional study. *Intern Med* 2012; 51: 1667–75.
- Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetes patients. *Diabetes*, 2005; 54: 3541–46.
- Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010; 363:1341-1350.
- Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007;30:1212–18.
- Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. *Diabetic Medicine* 2006;23:403–9.
- Targher G, Scorletti E, Mantovani A, Byrne CD. Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. *Metab Syndr Relat Disord* 2013; 11: 217-228.
- Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. *J. Clin. Endocrinol. Metab.* 2013; 98: 483–495.

- Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Semin Thromb Hemost* 2009;35:277-87.
- Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. *J Hepatol* 2010; 53: 713–718.
- Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. *Journal of Hepatology* 2006; 45 (6): 879–881.
- Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative laser treated retinopathy in type 2 diabetic patients. *Diabetologia* 2008; 51:444-50.
- Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology*. 1995;22:1714–1719.
- Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. *J Atheroscler Thromb* 2013; 20: 517-523.
- Testa MA, Simonson DC. Assessment of quality of life outcomes. *N Engl J Med* 1996; 334: 835-840.
- Tevar AD, Clarke C, Wang J, Rudich SM, Woodle ES, Lentsch AB, Edwards ML. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. *J Am Coll Surg* 2010; 210(4): 515-526.
- Than A, Newsome NP. Non-alcoholic fatty liver disease: when to intervene and with what. *Clinical Medicine*. 2015;15(2): 186–90.
- Thier SO. Forces motivating the use of health status assessment measures in clinical settings and related clinical research. *Med Care* 1992; 30 (Suppl): MS15-MS22.
- Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. *J Hepatol* 2012;56:255-66.
- Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, Frost G, Bell JD, Taylor-Robinson SD. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in nonalcoholic fatty liver disease. *World J Gastroenterol* 2006;12:5813–5819.
- Thulstrup AM, Norgard B, Steffensen FH, Vilstrup H, Sørensen HT, Lauritzen T. Waist circumference and body mass index as predictors of elevated alanine transaminase in Danes aged 30 to 50 years. *Dan Med Bull*. 1999;46:429-431.
- Tiikkainen M, Hakkinen AM, Korshennikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. *Diabetes* 2004;53(8):2169-76.
- Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends Endocrinol Metab* 2008;19:371-9.
- Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. *Am J Clin Nutr* 2005;81:35–42.
- Tiwari P, Mishra BN, Sangwan NS. Phytochemical and Pharmacological Properties of *Gymnema sylvestre*: An Important Medicinal Plant. *BioMed Research International* Volume 2014, Article ID 830285, 18 pages.
- Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. *Ann Intern Med* 2004;21:141:946-56.
- Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease, *Diabetes Care* 2007;30:734–43.
- Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. *Nutrition* 2007; 23: 46-52.
- Tovar AR, Torres N. The role of dietary protein on lipotoxicity. *Biochim. Biophys. Acta* 2010; 1801: 367–71.

- Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. *Biochim Biophys Acta* 2010; 1801: 299-310.
- Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. *Digestive Diseases and Sciences* 2011; 56 (1): 35–45.
- Tripathi N, Choudhary A, Agarwal R, Chandurkar P and Murab T. Effects of *Tinospora cordifolia* leaf Powder Supplementation on sugar level in non-diabetic obese women of Bhopal. *Bull. Env. Pharmacol. Life Sci.* 3 (2) 2014: 05-13.
- Trocho C, Pardo R, Rafecas I, Virgili J, Remesar X, Fernández-López JA, Alemany M. Formaldehyde derived from dietary aspartame binds to tissue components in vivo. *Life Sci.* 1998;63(5):337–49.
- Trojak A, Waluś-Miarka M, Woźniakiewicz E, Maciej T, Małecki MT, Idzior-Waluś B. Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes. *Med Sci Monit* 2013; 19: 1167-1172.
- Tsay HS, Agrawal DC. Tissue Culture Technology of Chinese Medicinal Plant Resources in Taiwan and their Sustainable Utilization. *Int J App Sci Eng* 2005; 3:215- 223.
- Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol* 1997; 27: 103-107.
- Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2011;305:1790-1799.
- Upadhyay AK, Kumar K, Kumar A, Mishra HS. *Tinospora cordifolia* (Willd.) Hook. f. and Thoms. (Guduchi) - validation of the Ayurvedic pharmacology through experimental and clinical studies; *International Journal of Ayurveda Research* 2010; 1 (2): 112-121.
- Utzschneider KM, Kahn SE. The role of insulin resistance in non-alcoholic fatty liver disease. *J Clin Endocrinol Metab* 2006;91: 4753–61.
- Valery PC, Powell E, Moses N, Volk ML, McPhail SM, Clark PJ, Martin J. Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. *BMJ Open* 2015;5: e007451. doi:10.1136/ bmjopen-2014-007451.
- Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and FibroTest. *Hepatology* 2007;46:32-36.
- Valls C, Iannaccone R, Alba E, Murakami T, Hori M, Passariello R, Vilgrain V. Fat in the liver: Diagnosis and characterization. *Eur Radiol* 2006;16:2292-308.
- Valtuena S, Pellegrini N, Ardigo D, del Rio D, Numeroso F, Scazzina F, Monti L, Zavaroni I, Brighenti F. Dietary glycemic index and liver steatosis. *Am. J. Clin. Nutr.* 2006; 84: 136–142.
- Van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. *Hepatology* 2008; 48: 449-457.
- Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? *Annals of Internal Medicine* 1989; 111 (6): 473–478.
- Vanni E, Bugianesi E. Obesity and liver cancer. *Clin Liver Dis.* 2014; 18: 191-203.
- Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. *Therap Adv Gastroenterol* 2011; 4: 249-263.
- van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: Comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. *Radiology* 2010;256:159-68.
- Vedavathy S. *J Ethnopharmacol*, 1991; 33,193-6.
- Vega GL, Chandalia M, Szczepaniak LS, Grundy SM (2008) Effects of N-3 fatty acids on hepatic triglyceride content in humans. *J Investig Med* 56: 780-785.
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;34: 274-285.
- Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. *Trends Mol. Med.* 2006; 12: 555–558.

- Vijayaraghavan. Treatment of dyslipidemia in patients with type 2 diabetes. *Lipids in Health and Disease* 2010 9:144.
- Vilar L, Oliveira CP, Faintuch J, Mello ES, Nogueira MA, Santos TE, Alves VA, Carrilho FJ. High-fat diet: A trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects. *Nutrition*. 2008;24(11-12):1097-1102.
- Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. *Hepatology* 2005; 42 (2): 473–480.
- Vishwanathan V, Kadiri M, Medimpudi S, Kumpatla S. Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in South Indian diabetic subjects. *International Journal of Diabetes In Deveoping Countries* 2010;30(4):208-212.
- Volk ML, Fisher N, Fontana RJ. Patient knowledge about disease self-management in cirrhosis. *Am J Gastroenterol* 2013;108: 302–5.
- Vos MB, Lavine JE. Dietary fructose in non-alcoholic fatty liver disease. *Hepatology* 2013; 57: 2525-2531.
- Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes* 2002; 51: 1889-1895.
- Vuksan V, Jenkins DJA, Spadafora P, editors. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes: A randomized controlled metabolic trial. *Diab Care*. 1999;22:913–9.
- Vuksan V, Sievenpiper J.L, Owen R, editors. Beneficial effects of viscous dietary fiber from Konjac- mannan in subjects with the insulin resistance syndrome: Results of a controlled metabolic trial. *Diab Care*. 2000;23:9–14.
- Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: selected practical issues in their management. *Hepatology* 2009;49:306-317.
- Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. *Obes Res* 2004;12 Suppl:151S–162S.
- Wadden TA, Foster GD. Behavioral treatment of obesity. *Med Clin North Am* 2000;84:441-461.
- Wadkar KA, Magdum CS, Patil SS, Naikwade NS. Antidiabetic potential and Indian medicinal plants. *J Herbal Med and Toxicol* 2008; 2: 45-50.
- Wagenknecht LE, Scherzinger AL, Stamm ER, Hanley AJ, Norris JM, Chen YD, Bryer-Ash M, Haffner SM, Rotter JI. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. *Obesity* 2009;17:1240-6.
- Wainwright P. Non-alcoholic fatty liver disease and type 2 diabetes: An overview of the problem. *Journal of Diabetes Nursing* 2015; 19: 195–9.
- Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990;12(5):1106–10.
- Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. *Am J Epidemiol* 1995; 142: 699–708.
- Wei Y, Wang D, Topczewski F, Pagliassotti M. Fructose-mediated stress signaling in the liver: implications for hepatic insulin resistance. *J Nutr Biochem* 2007; 18:1–9.
- Westphal SA. Non-alcoholic fatty liver disease and type 2 diabetes. *European Endocrinology. Touch briefings* 2008; 70-73.
- World Health Statistics 2014. Geneva, World Health Organization, 2014.
- WHO, 2014. Noncommunicable diseases country profiles, 2014.
- WHO, 2013. Global action plan for the prevention and control of noncommunicable diseases 2013-2020.
- WHO, 2011. Global status report on noncommunicable diseases 2010. Geneva, World Health Organization.
- Global data on visual impairments 2010. Geneva, World Health Organization, 2012.
- The global burden of disease: 2004 update. Geneva, World Health Organization, 2008
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004; 363: 157–63.

- WHO STEPwise approach to surveillance (STEPS). Geneva, World Health Organization (WHO), 2008b.
- WHO/UNICEF/UNU. Iron deficiency anaemia: assessment, prevention, and control. Geneva: World Health Organization 2001.
- Waist circumference and waist hip ratio: report of a WHO expert consultation, Geneva, 8th to 11th December, 2008.
- Weiß J, Rau M, Geier A: Non-alcoholic fatty liver disease— epidemiology, clinical course, investigation and treatment. *Dtsch Arztebl Int* 2014; 111: 447–52.
- Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005; 115: 1111-1119
- Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. *Hepatology* 2005; 41:372–379.
- Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin- 6 levels in human nonalcoholic steatohepatitis. *Am J Gastroenterol* 2008; 103: 1372-1379.
- Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of non-alcoholic steatohepatitis: present and future. *Hepatology* 2007; 46 (2): 582–589.
- Wieckowska A, Feldstein AE. Diagnosis of non-alcoholic fatty liver disease: invasive versus non-invasive. *Seminars in Liver Disease* 2008; 28 (4): 386–395.
- Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. *Hepatology* 2006; 44 (1): 27–33.
- Williams CD, Stenger J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011;140:124-131.
- Williams R. Global challenges in liver disease. *Hepatology* 2006; 44: 521–6.
- Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and non-alcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes Care* 2011;34: 1139-44.
- Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ, eds. *Handbook of Obesity Treatment*. New York, NY: Guilford Press; 2002: 301-316.
- Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. *Ann Hepatol* 2013;12: 256-262.
- Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. *J Gastroenterol Hepatol* 2013; 28: 18-23.
- Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. *Gut* 2010; 59: 969–974.
- Wu T, Hai-Yan Song, Hua-Feng Wei, Yang M, Song-Hua He, Guang Ji. The Glucose Metabolism in Metabolic Syndrome Patients with Non-Alcoholic Fatty Liver Disease. *Global Journal of Gastroenterology & Hepatology*, 2014; 2: 19-28.
- Wu CC, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, Zheng CM, Diang LK, Lu KC. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. *Tohoku J Exp Med* 2011; 223: 153-159.
- Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. *Cancer Res* 2004;64:6461–8.
- Wylie-Rosett J, Aebersold K, Conlon B, Isasi CR, Ostrovsky NW. Health effects of low-carbohydrate diets: Where should new research go? *Curr. Diabetes Rep* 2012; 13: 271–278.
- Xue-ying F; Quan-sen Z; Hong-xiang Z. College of Public Health, Harbin Medical University. Survey on knowledge, attitude and practice (KAP) of nonalcoholic fatty liver diseases among residents in Harbin. *Chinese Journal of Public Health Management*. 2014.

- Yadav RNS, Agarwala M. Phytochemical analysis of some medicinal plants. *Journal of Phytology* 2011; 3(12): 10-14.
- Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. *Liver Transpl* 2010; 16: 431-439.
- Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. *J Am Coll Cardiol* 2008; 52: 988-996.
- Yang M, Gong S, Ye SQ, Lyman B, Geng L, Chen P, Li DY. Non-Alcoholic Fatty Liver Disease in Children: Focus on Nutritional Interventions. *Nutrients* 2014; 6: 4691-4705.
- Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS, Yang SS. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. *Nutrition* 2011;27:943–948.
- Yasui K, Hashimoto E, Komorizono Y, Koike K, Arie S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011;9: 428-433.
- Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. *Scand J Gastroenterol* 2009; 44 (4): 471-477.
- Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. *World J Gastroenterol* 2014; 20(7): 1756-1767.
- Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake. *Gastroenterology Research and Practice* 2012; Article ID 859697, 8 pages.
- Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol* 2009; 24: 248-254.
- Yeh G.Y, Eisenberg D.M, Kaptchuk T.J, Phillips R.S. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diab Care*. 2003;26:1277–94.
- Yoneda M, Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). *Gut* 2007;56:1330-1331.
- Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Kobayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo S, Nakajima A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). *Dig Liver Dis* 2008; 40: 371-378.
- Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. *Journal of Gastroenterology* 2007; 42 (7): 573–582.
- Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. *Phytomed*. 1996;3:241–3.
- York LW, Puthalapattu S, Wu GY. Nonalcoholic fatty liver disease and low-carbohydrate diets. *Annu Rev Nutr*. 2009;29:365-379.
- Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. *Clinical Gastroenterology and Hepatology* 2004; 2: 262-265.
- Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, McCullough AJ. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. *Modern Pathology* 1998; 11 (6): 560– 565.

- Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. *Am J Gastroenterol.* 2001;96:2199-2205.
- Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. *Am J Gastroenterol.* 2001;96:579-583.
- Zandi M, Adib-Hajbagheri M, Memarian R, Nejhad AK, Alavian SM. Effects of a self-care program on quality of life of cirrhotic patients referring to Tehran Hepatitis Center. *Health Qual Life Outcomes* 2005;3:35.
- Zatloukal K, Stumtner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, Denk H. The keratin cytoskeleton in liver diseases. *J. Pathol.* 2004; 204: 367–76.
- Zeb I, Katz R, Nasir K, Budoff M. Relation of Non-Alcoholic Fatty Liver Disease to the Metabolic Syndrome: The Multi- Ethnic Study of Atherosclerosis. *JACC* 2013; 61: (10): E1428.
- Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. *J Hepatol* 2007; 47: 711-717.
- Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. *Hepatology* 2008;48:1791–1798.
- Zelber-Sagi S, Ratzu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. *World J Gastroenterol* 2011; 17: 3377-3389.
- Zelber-Sagi S, Lotan R, Shlomei A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven year prospective follow-up. *J Hepatol* 2012; 56: 1145–51.
- Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signalling. *Journal of Clinical Investigation* 2006; 116 (3): 607–614.
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doeber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 2001;108: 1167-1174.
- Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J. Gastroenterol.* 2008; 14: 6395–6400.
- Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. *J Int Soc Sports Nutr.* 2006;3:45–53.
- Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001; 414: 782-787.
- Ziolkowski M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; 41: 48-54.
- Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. *Am J Clin Nutr* 2007;86:285–300.
- Zuniga J, Cancino M, Medina F, Varela P, Vargas R, Tapia G, Videla LA, Fernandez V. N-3 pufa supplementation triggers ppar- α activation and ppar- α /nf-kappaB interaction: Anti-inflammatory implications in liver ischemia-reperfusion injury. *PLoS One* 2011, 6, e28502.